 
 
 
Protocol : J2T -MC- KGAK  
 
 
A Phase 3, 16- week, Randomized, Double -Blind, Placebo- Controlled, Parallel -
Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in 
Adult Patients with Moderate -to-Severe Atopic Dermatitis 
 
 
[STUDY_ID_REMOVED]  
 
 
Approval Date: 05- Aug-2020  
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical 
investigation of lebrikizumab (LY3650150 /DRM06 ), unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries. 
Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation reg arding release/redaction prior to any public release.
In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries .
Protocol Title: A Phase 3, 16 -week, Randomized, Double -Blind, Pl acebo -Controlled, Parallel -
Group Study  to Assess the Im pact of Lebrikizumab on Vaccine Responses in 
Adult Patients wi th Moderate -to-Severe Atopic Dermat itis
Protocol Numb er:J2T-MC-KGAK /DRM06 -AD18
Amendment Number: This is the init ial protocol .
Compound :lebrikizumab (LY3650150 /DRM06 )
Study Phase: 3
Short Title: A Phase 3, 16 -week, Randomized, Double -Blind, Pl acebo -Controlled, Parallel -
Group Study  to Assess the Im pact of Lebrikizumab on Vaccine Responses in Adult 
Patients wi th Moderate -to-Severe Atopic Dermat itis
Sponsor Name: Eli Lilly  and Com pany
Legal Registered Address: Indianapo lis, Indiana USA 46285
Regulatory Agency Identifier Number(s)
IND: 119866
EudraCT: 2020-002572-12
Approval Date: Protocol Electronically Signed and Approved by Lilly ondate provi ded bel ow.
Approval Date: 05-Aug-2020 GMT
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
2Medical Monitor Name and Contact Information will be provided separately.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
3Table of Contents
1. Protocol Summary ...................................................................................................... 6
1.1. Synopsis ....................................................................................................................... 6
1.2. Schema ....................................................................................................................... 10
1.3. Schedule of Act ivities (SoA) ...................................................................................... 11
2. Introduction .............................................................................................................. 23
2.1. Study  Rati onale .......................................................................................................... 23
2.2. Background ................................................................................................................ 23
2.2.1. Clinical Manifestations of Atopic Dermat itis.............................................................. 24
2.2.2. Treatment for Atopic Dermat itis................................................................................. 25
2.3. Benefit/Risk Assessment ............................................................................................ 25
3. Objectives and Endpoints ......................................................................................... 27
4. Study Design ............................................................................................................. 29
4.1. Overall Design ............................................................................................................ 29
4.2. Scientific Rati onale f or Study  Design ......................................................................... 30
4.2.1. Parti cipant Input into Desi gn...................................................................................... 31
4.3. Justification for Dose .................................................................................................. 31
4.4. End of Study  Definit ion.............................................................................................. 31
5. Study Population ...................................................................................................... 32
5.1. Inclusio n Cri teria........................................................................................................ 32
5.2. Exclusio n Cri teria....................................................................................................... 33
5.3. Lifest yle Considerat ions............................................................................................. 36
5.4. Screen Failures ........................................................................................................... 36
5.4.1. Rescr eening for Individuals Who Failed Screening ..................................................... 36
6. Study Intervention .................................................................................................... 38
6.1. Study  Intervent ions Administered ............................................................................... 38
6.1.1. Study  Drugs ................................................................................................................ 38
6.1.2. Vaccine Products ........................................................................................................ 38
6.1.3. Instructi ons for Administration in the Clinic ............................................................... 39
6.1.4. Instructi ons for Administration at Home ..................................................................... 39
6.1.5. Packaging and Labeling .............................................................................................. 39
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 39
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 40
6.4. Study  Intervent ion Compliance ................................................................................... 41
6.5. Concomitant Therapy .................................................................................................41
6.5.1. Permi tted and Prohibited Treatments and Procedures .................................................. 41
6.5.2. Background Treatment: Non -Medi cated Moisturi zers................................................. 42
6.5.3. Rescue Treatment for Atopic Dermat itis..................................................................... 42
6.6. Dose Modificat ion...................................................................................................... 43
6.7. Intervention after the End of the Study ........................................................................ 43
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 44
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
47.1. Discontinuati on of  Study  Intervent ion........................................................................ 44
7.1.1. Criteria for Tem porary  Discon tinuation of Study  Drug ............................................... 44
7.1.2. Criteria for Perm anent Discont inuat ion of Study  Drug ................................................ 45
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 47
7.2.1. Discontinuati on of  Inadvertent ly Enrolled Participants ............................................... 48
7.3. Lost to Follow up ....................................................................................................... 48
8. Study Assessments and Procedures ......................................................................... 49
8.1. Efficacy Assessments .................................................................................................49
8.1.1. P rimary Outcome Measures: Vaccine Responses ........................................................ 49
8.1.2. Secondary  Outcom e Measures: Efficacy ..................................................................... 49
8.1.3. Patient-Reported Outcomes ........................................................................................ 50
8.2. Safety Assessments .................................................................................................... 53
8.2.1. Physical Examinat ions................................................................................................ 53
8.2.2. Vital Signs.................................................................................................................. 53
8.2.3. Clinical Safety  Laboratory  Assessments ..................................................................... 53
8.2.4. Systemic Hypersensit ivity Reactions .......................................................................... 54
8.2.5. Hepati tis B Test ing and Monitoring ............................................................................ 55
8.2.6. Hepati tis C Test ing and Monitoring ............................................................................ 55
8.2.7. Hepati c Safet y Moni toring .......................................................................................... 56
8.2.8. Serious Infect ions and Opportunistic Infections .......................................................... 58
8.3. Adverse Events and Serious Adverse Events .............................................................. 58
8.3.1. Time Period and Frequency  for Collect ing AE and SAE 
Inform ation................................................................................................................. 58
8.3.2. Method of Detecting AEs and SAEs ........................................................................... 59
8.3.3. Follow-up of  AEs and SAEs ....................................................................................... 59
8.3.4. Regulatory  Reporting Requirements for SAEs ............................................................ 59
8.3.5. Pregnancy ................................................................................................................... 60
8.3.6. Adverse Events of Special Interest .............................................................................. 60
8.3.7. Product Complaint s.................................................................................................... 60
8.4. Treatment of Overdose ............................................................................................... 61
8.5. Pharmacokinet ics........................................................................................................ 61
8.6. Pharmacodynamics ..................................................................................................... 62
8.7. Genet ics..................................................................................................................... 62
8.8. Biomarkers ................................................................................................................. 62
8.9. Immunogenicit y Assessments ..................................................................................... 63
8.10. Medical Resource Utilizat ion and Healt h Economics .................................................. 63
9. Statistical Considerations ......................................................................................... 64
9.1. Statistical Hypotheses ................................................................................................
.64
9.2. Sample Si ze Determinat ion......................................................................................... 64
9.3. Popul ations for Analyses ............................................................................................ 64
9.4. Statistical Analyses ..................................................................................................... 65
9.4.1. General Considerations ............................................................................................... 65
9.4.2. Co-Primary Analyses .................................................................................................. 67
9.4.3. Secondary  Analyses .................................................................................................... 67
9.4.4. Exploratory  Analyses .................................................................................................. 68
9.4.5. Safety Analyses .......................................................................................................... 68
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
59.4.6. Pharmacokinet ic Analyses .......................................................................................... 68
9.4.7. Immunogenicit y Data Analysis ................................................................................... 69
9.4.8. Other Analyses ........................................................................................................... 69
9.5. Interim Analyses ......................................................................................................... 69
9.6. Data Monitoring Committee (DMC) ........................................................................... 70
10. Supporting Documentation and Operational Considerations ................................ 71
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Conside rations............................................................................................................ 71
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 71
10.1.2. Financial Disclo sure................................................................................................... 71
10.1.3. Inform ed Consent Process .......................................................................................... 72
10.1.4. Data Protection ........................................................................................................... 72
10.1.5. Committee Structure ................................................................................................... 72
10.1.6. Disseminat ion of Clinical Study  Data ......................................................................... 73
10.1.7. Data Qualit y Assurance .............................................................................................. 73
10.1.8. Source Documents ...................................................................................................... 74
10.1.9. Study  and Si te Start and Cl osure ................................................................................. 75
10.1.10. Publicat ion Policy ....................................................................................................... 75
10.1.11. Invest igator Informat ion............................................................................................. 75
10.1.12. Long -Term  Sample Retent ion..................................................................................... 75
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 77
10.3. Appendix 3: Adverse Events: Definit ions and Proc edures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 81
10.3.1. Definit ion of AE......................................................................................................... 81
10.3.2. Definit ion of SAE ....................................................................................................... 82
10.3.3. Recording and Fo llow-Up of AE and/or SAE ............................................................. 83
10.3.4. Reporting of SAEs ...................................................................................................... 85
10.4. Appendix 4: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... 86
10.4.1. Definit ions.................................................................................................................. 86
10.4.2. Contraception Guidance .............................................................................................. 86
10.4.3. Collect ion of Pregnancy  Information.......................................................................... 86
10.5. Appendix 5: Reco mmended Laboratory Test ing for Systemic 
Hypersensi tivity Events .............................................................................................. 88
10.6. Appendix 6: Liver Safet y: Suggested Actions and Follow -Up 
Assessments ............................................................................................................... 90
10.7. Appendix 7: Examples of Infect ions That May  Be Considered 
Opportuni stic.............................................................................................................. 92
10.8. Appendix 8: American Academy of Dermatology  Consensus 
Criteria for Chroni c Atopi c Derm atitis........................................................................ 94
10.9. Appendix 9: Provisio ns for Changes in Study  Conduct During 
Except ional Circumstances ......................................................................................... 96
10.10. Appendix 10: Abbreviat ions..................................................................................... 100
11. References ............................................................................................................... 105
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
61. Protocol Summary
1.1. Synopsis
Protocol Title: A Phase 3, 16 -week, Randomized, Double -Blind, Pl acebo -Controlled, Parallel -
Group Study  to Assess the Im pact of Lebrikizumab on Vaccine Responses in Adult Patients with 
Moderate -to-Severe Atopic Dermat itis
Short Title: same as the protocol tit le
Rationale :
Study  J2T-MC-KGAK (KGAK) is a Phase 3, randomized, double -blind, pl acebo -controlled 
study  to assess the impact of lebrikizumab on vaccine immune responses in adult pat ients with 
moderate -to-severe atopic dermat itis (AD) .This study  will evaluate the effect of lebrikizumab 
treatm ent on 2 vaccines co mmo nly used in adul ts wi th moderate to severe AD :
Tdap: Diphtheria and Tetanus Toxoids and Acellular P ertussis Vaccine Adsorbed
(Sanofi) , and
MCV: Meningococcal (Groups A, C, Y, and W -135) Oligosaccharide Diphtheria 
CRM197 Conjugate Vaccine (GlaxoSmit hKline) .
In addit ion, thi s study  will further assess the efficacy  and safet y of lebrikizumab in patients with 
moderate -to-severe AD.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
7Objectives and Endpoint s
Objectives Endpoints
Co-Prim ary
To compare the seroresponses to the Tdap and 
MCV between lebrikizumab- treated and 
placebo -treated participants with 
moderate -to-severe ADThe percentage of participants who:
1.Develop a booster response to tetanus 
toxoid 4 weeks after the administration of the 
Tdap vaccine (Week 16)
Booster response is defined as:
o≥4-fold increase in anti -tetanus toxoid 
IgG antibody concentration if the pre -
vaccination level wa s >0.10 IU/mL and 
≤2.7 IU/mL; 
OR
o≥2-fold increase in anti -tetanus toxoid 
IgG antibody concentration if the pre -
vaccination level was >2.7 IU/mL; 
OR 
o≥4-fold increase in anti -tetanus toxoid 
IgG antibody concentration and a post -
vaccination level ≥0.10 IU/mL if the pre -
vaccination level was ≤0.10 IU/mL
2.Have positive antibody response to MCV 
(group C serum  bactericidal antibodie s)
4weeks after the administration of the 
vaccine (Week 16)
Positive antibody response to MCV is defined 
as:
opost-vaccin ation hSBA titer ≥4 times the 
LLOQ, if the pre -vaccination hSBA titer 
is less than the LLOQ;
OR
opost-vaccination hSBA titer ≥4 times the 
pre-vaccination titer, if the pre -
vaccination hSBA titer is greater than or 
equal to the LLOQ
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
8Objectives Endpoints
Secondary
To compare the efficacy of lebrikizumab with 
that of placebo in treatment of participants
with moderate -to-severe AD, as measured by :Percentage of participants at Week 16 achieving :
an IGA score of 0 or 1 and a reduction of 
≥2points from baseline
EASI -75
EASI -90
≥4-point improvement from baseline in 
Pruritus NRS score 
Percentage change from baseline to Week 16 in:
EASI
Pruritus NRS score
Change from baseline in:
Percent BSA
Sleep -Loss score
To compare the patient -reported outcomes 
between lebrikizumab-t reated and 
placebo -treated participants with 
moderate -to-severe AD, as measured by :Change from baseline by visit in:
PROMIS® Anxiety measure
PROMIS® Depression measure
Abbreviations: AD = atopic dermatitis; BSA = Body Surface Area; EASI = Eczema Area and Severity Index; 
EASI -75 = ≥75% reduction from baseline in EASI score; EASI -90 = ≥90% reduction from baseline in EASI 
score; hSBA = human complement serum bactericidal assay; IGA = Investigator Global Assessment; 
IgG=immunoglobulin G; LLOQ = lower limit of quantitation; MCV = Meningococcal (Groups A, C, Y, and W -
135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (GlaxoSmithKline) ; NRS =Numeric Rating 
Scale; PROMIS = Patient -Reported Outcomes Measurement Information System; Tdap =Diphtheria and 
Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (Sanofi) .
Overall Design
KGAK will last approximately 16 weeks and will have 3 study  periods:
Screening
Treatment
Safety follow-up
Depending on the preference of the study  site or the study  parti cipant, some of the study  visits 
may be performed eit her rem otely  or on si te, as indi cated in the Schedule of Act ivities(SoA) . In 
addition,provisio ns for except ional circumstances (such as pandemics or natural disasters) are 
provi ded in Appendix 10.9.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
9Remote vi sits may be conducted as fo llows:
virtually (i.e., via telephone or telemedicine tools), and
at a mobile locat ion (e.g., a participant’s ho me), if permi tted by  local laws and 
regul ations.
Parti cipants will receive le brikizumab or matching placebo via subcu taneous inject ion. The 
lebrikizumab doses will be as fo llows:
At randomizat ion/baseline and Week 2: loading dose of500 m g
At Weeks 4 through 14: 250 mg once every  2weeks (Q2W)
During remote visits, s tudy participants will have an option of administering the study  drug 
either themselves, or having a caregiver or a mobile ho me health care provider administer it. 
Prior to at -home administration, p articipants and /orcaregivers willbe adequately  trained on the 
study  drug administrati on at the clinical site .
Both vaccines will be administered at Week 12 at the clinical site. Vaccine inject ions will be 
given per local vaccinat ion gui delines and practi ces and :
shoul d not be injected in body locationswith active AD or other skin lesio ns
shoul d be injected in a location different from that for the study  drug administration
Disclosure Statement : This is a parallel, 2 -arm treatm ent study  that i s double -blinded .
Number of Participant s:
Approximately  240 participants will be randomly  assigned to study  drug.
Intervention Groups and Duration :
Parti cipants will be randomized in 1:1 ratio to receive eit her lebrikizumab or pl acebo. All  of the 
participants will receive both of the vaccines (Tdap and MCV).
Data Monitoring Committee: Yes; a Data Safet y Moni toring Board (DSMB) will be used in 
this study . (A DSMB is a ty pe of Data Moni toring Committee.)
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
101.2. Schema
Abbreviations: MCV = Meningococcal (Groups A, C, Y, and W -135) Oligosaccharide Diphtheria CRM197 
Conjugate Vaccine (GlaxoSmithKline) ; Q2W = once ever y 2 weeks; Tdap = Diphtheria and Tetanus Toxoids 
and Acellular Pertussis Vaccine Adsorbed (Sanofi) .
aLebrikizumab loading dose of 500 mg will be administe red at baseline and Week 2.
bThe safety follow -up will occur at Week 26 (or approximately 12 weeks after last study drug injection). See 
Section 4.4for completion of study definitions.
cIf eligible, participants can continue to the long -term extension study (DRM06 -AD07/J2T -DM- KGAA). See 
Section 4.4for completion of study definitions.

CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
111.3. Schedule of Activities (SoA)
The S oAdescribed below should be followed for all participants enrolled in Study KGAK. However, for those participants whose participation in 
this study is affected by exceptional circumstances (such as pandemics or natural disasters), please refer to Appendix 10.9 for additional guidance.
Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
Informed consent X
Inclusion and exclusion 
criteria, review and 
confirmX X
Demographics X
Preexisting conditions 
and medical historyX
Prespecified medical 
history  (indication and 
history  of interest)X
Review of immunization 
record XApplies only to Tdap ,MCV , 
BCG, or any live (attenuate d)
vaccine .
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
12Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
Prior treatments for AD XIncludes medications and 
procedures .
Concomitant therapies X X X X X X X X X X X XIncludes medications of 
special interest such as TCS 
and TCI and procedures.
Adverse events (AEs) X X X X X X X X X X X XCollection for AEs associated 
with vaccinations will begin 
at Week 12.
For AESIs, additional data are 
collected (Section 8.3.6 ).
Physical Evaluation
Height X X
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
13Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
Weight X X X
Vital signs X X X X X X X See Section 8.2.2 for details.
Physical examination X X XSee Section 8.2.1 for details.
Additional symptom -directed 
physical examinations may be 
conducted at the discretion of 
the investigator.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
14Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
Patient Education
Diary  education X
Train participant and/or 
caregiver on study drug 
administrationXApplicable only when 
participant chooses to self -
administer the study drug or 
have a caregiver administer it.
Patient Diary (Electronic)
Patient diary dispensed XThe electronic patient diary 
will be used to record the 
following:
Patient- reported 
outcomes (PROs)
Information about at -
home study drug 
administration
PRO d iary compliance 
checkX X X X X X X X X XThis diary compliance check 
includes checking for 
completion of the PRO 
assessments. For details about 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
15Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
those assessments, see 
Section 8.1.3 and the PRO 
section of the SoA.
Drug Administration 
diary  compliance checkX X X X XThis diary compliance check 
includes checking for study 
drug compliance.
Participant will need to 
complete this diary any time 
the study  drug is administered 
at home (regardless of who 
administered the drug at 
home —the participant, 
caregiver, or mobile home 
health care provider).
Diary  return (patient to 
site)X XParticipant would need to 
visit the site to return the 
electronic diary.
Participants need to return the
electronic diary device only if 
they are notrolling into the 
long-term extension study 
(DRM06 -AD07 /J2T-DM-
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
16Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
KGAA).
Patient -Reported Outcomes (Electronic Diary at Home)
Pruritus NRS Daily  (should be completed at approximately the same time ever y day)Initial electronic diary entries 
for Pruritus NRS should be 
completed a m inimum of 4 of
7days before randomization.
PROs should be completed 
prior to any other study 
assessments.
Sleep -Loss Daily  (should be completed at approximately the same time ever y day)Initial electronic diary entries 
for Sleep -Loss should be 
completed a minimum of 4 of
7 day s before randomization.
PROs should be completed 
prior to any other study 
assessments.
Skin Pain NRS Daily  (should be completed at approximately the same time every day)Initial electronic diary entries 
for Skin Pain NRS should be 
completed a minimum of 4 of
7days before randomization.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
17Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
PROs should be completed 
prior to any other study 
assessments.
Patient-Oriented Eczema 
Measure (POEM)WeeklyPROs should be completed 
prior to any other study 
assessments.
Patient -Reported Outcomes (Electronic Tablet on Site )
PROMIS ®(Patient -
Reported Outcomes 
Measurement 
Information System) 
Anxiety MeasureX X XPROs should be completed 
prior to any other study 
assessments.
PROMIS ®Depression 
MeasureX X XPROs should be completed 
prior to any other study 
assessments.
Clinician-Administered Assessments (Electronic Tablet on Site )
Investigator Global 
Assessment (IGA) X X X X X XThe IGA must be conducted 
prior to conducting the EASI 
and BSA assessments. 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
18Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
Eczema Area and 
Severity  Index (EASI) X X X X X X
Body Surface Area 
(BSA) X X X X X X
Laboratory Tests and Sample Collections
Hematology X X X X X
Clinical Chemistry X X X X X
Urinaly sis X X X X X
Serum pregnancy XOnly f or women of 
childbearing potential
(Section 8.2.3.1 and 
Appendix 10.4).
Urine pregnancy (local) X X X X X XOnly f or women of 
childbearing potential
(Section 8.2.3.1 and 
Appendix 10.4).
HIV screening tests X
Hepatitis C Virus (HCV) 
screening testsXHCV RNA will be measured 
to confirm positive 
hepatitis C virus antibody 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
19Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
(Section 8.2.6 ).
Hepatitis B Virus (HBV) 
screening testsXIncludes testing for HBsAg ,
anti-HBc , and anti -HBs .
HBV DNA X XOnly for participants who are 
anti-HBc reactive and anti -
HBs nonreactive at screening 
(Section 8.2.5 ).
Total IgG X
Total IgA X
Anti-tetanus toxoid IgG 
antibodyX X XAt Week 12, collect this 
sample before the vaccine 
administration.
Meningococc alGroup C 
serum bactericidal 
antibodies(human 
complement serum 
bactericidal assay X X XAt Week 12, collect this 
sample before the vaccine 
administration.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
20Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
[hSBA ])
Pharmacokinetic (PK) 
samplesX X X X X XCollect samples before 
dosing. See Section 8.5
for more information 
about the PK testing .
In case of systemic 
hypersensitivity 
reactions, additional PK 
samples willneed to be 
collected (Section 8.2.4 , 
Appendix 10.5).
Immunogen icity (ADA) 
samples X X X X X XCollect samples before 
dosing. See Section 8.9
for details.
In case of systemic 
hypersensitivity 
reactions, additional 
immunogenicity samples 
will need to be collect ed 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
21Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
(Section 8.2.4 , 
Appendix 10.5).
Stored Samples
Pharmacogenetics sample X
Randomization and Dosing
Randomization X
Administer study drug X X X X X X X XDuring remote visits , 
participant can choose to self -
administer the assigned study 
drug (lebrikizumab or 
placebo) or have a caregiver 
or the mobile home health 
care provider administer it.
See Section 6.1.4 for more 
information about at -home 
administration.
Participants and/or caregivers 
need to be adequately trained 
on injection technique prior to 
administer inginjections.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
22Notes:
Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.
For early  terminations (ETs) that occur before the last visit in treatment period, see the activities listed for ET in this table.
Visit 801 is only for study participants who are terminating early or not rolling into the long -term extension study (DRM06 -AD07 /J2T-DM-KGAA) .
Visit number 1 2 3* 4 5* 6* 7* 8 9* 10 ET V801 * Comments
Weeks from
randomizationScreening 
(-4)Baseline
/Day  12 4 6 8 10 12 14 16 ETSafety 
follow -up
Week 26 (or 
approximately 
12 weeks after
last study drug 
injection ) * = visit may be conducted 
remotely or on site , per 
preference of the study siteor 
participant . 
See Section 4.1for details 
about remote visits.
Days from randomization ≤30 — 15 29 43 57 71 85 99 113 N/A
Visit interval tolerance 
(days)— ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 N/A ±3
Mobile home health care 
provider would observe the 
participant’s or caregiver’s 
first attempt at administering 
the study  drug .
Administer vaccines: 
Tdap and MCVXSee Section 6.1.2 for location 
of vaccine injections.
Participant/caregiver 
return sstudy drug and 
injection suppliesX X X X X XIf study drug was 
administered at home by 
participant or car egiver , the 
injection supplies should be 
saved and returned at the next 
on-site visit.
Abbreviations: AD = atopic dermatitis; ADA = antidrug antibodies; AESI = adverse event of special interest; anti-HBc = hepatitis B core antibody ; anti-
HBs =hepatitis B surface antibody; BCG = Bacillus Calmette -Guerin; HBsAg = hepatitis B surface antigen; IgA = immunoglobulin A; 
IgG=immunoglobulin G; MCV = Meningococcal (Groups A, C, Y, and W -135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
(GlaxoSmithKline) ; N/A = not applicable; NRS = Numeric Rating Scale; SoA = Schedule of Activities; TCI = topical calcineurin inhibitors; TCS = topical 
corticosteroids; Tdap = Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (Sanofi) ; V = visit .
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
232. Introduction
2.1. Study Rationale
To date, no vaccine -response studi es have been conducted for lebrikizumab .Because 
lebrikizumab suppresses interleukin (IL)-13 si gnaling, a potenti al immuno modulator effect, there 
is a need to assess immune response to vaccinat ions in patients receiving this drug. 
Study  J2T-MC-KGAK (KGAK) is a Phase 3 , randomized, double -blind, placebo -controlled
study  to assess the impact of lebrikizumab on vaccine immune responses in adult patients with 
moderate -to-severe atopic dermat itis(AD) .This study  will evaluate the effect of lebrikizumab 
treatm ent on 2 vaccines commo nly used in adul ts wi th moderate to severe AD :
Tdap: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
(Sanofi) ,and
MCV: Meningococcal (Groups A, C, Y, and W -135) Oligosaccharide Diphtheria 
CRM197 Conjugate Vaccine (GlaxoSmit hKline) .
In addit ion, thi s study  will further assess the efficacy  and safet y of lebrikizumab in patients with 
moderate -to-severe AD. 
2.2. Background
Atopic derm atitis is a co mplex disease that is considered an autoimmune disorder ( Mitterman et 
al. 2004 ) and i s determined by genet ic, environmental, and immuno logic factors (Werfel et 
al.2016; Simo n et al. 2019). Atopic dermat itis isone of the m ost comm on chroni c medical 
diseases ; 2% to 20% of adults are affected, and the prevalence appears to have increased over the 
past 3to 4decades (Willia ms et al. 2008 ), with some geographic variabilit y.
Genet ic studies of AD ( Bieber 2012; Auriemma et al.2013; Weidinger et al. 2018) have shown 
that genes encoding for cy tokines invo lved in the regulat ion of the immune system (IL -4, IL -5, 
and IL -13) are strongly associated with the develo pment of AD ( Novak et al. 2002; He et al. 
2003; Hummelsho j et al. 2003). In addition, variants of genes that encode for proteins invo lved 
in skin barrier funct ion such as filaggrin (FLG) and loricrin (LOR) are also associated with AD 
(Van Bever and Llanora 2011). Since FLG plays a central role in skin barrier inte grity, loss of 
funct ion mutations of the FLG gene is considered a major contributor to the development of 
early  childhood AD (Bieber 2008; Tanei 2009; Bi eber 2012; Flohr and Irvine 2013). 
Reduced epithelial barrier funct ion, which represents the first lin e of protecti on against the 
environment, is thought to lead to sensit ization to environmental allergens, associated with 
elevated immunogl obulin E (IgE) . Elevated IgE is present in up to 80% of all pat ients with AD, 
particularly in children (Werfel et al. 
2016), and is consistent with the presence in the skin of the 
following:
Type 2 cy tokines :
oIL-4
oIL-5
oIL-9
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
24oIL-13
oIL-25
oIL-31
oIL-33, and 
othymic stromal lymphopoietin (TSLP) ,and
inflammat ion. 
Type 2 cy tokines increase epidermal thickening, sensit ization, inflammat ion, and pruri tus and 
decrease the expressio n of ant imicrobial pept ides and the barrier proteins FLG, LOR, and 
involucrin. I nterleukin -13 in parti cular can reduce epithelial integrit y and barrier function 
through downregulat ion of FLG, LOR, and invo lucrin (Kim et al.2008) and can act on 
keratinocy tes in the skin to downregulate their different iation (Howell et al. 2008). 
Interleukin -13 also induces T -cell chemoattractants that mediate T-cell infiltrat ion into AD 
lesions (Purwar et al. 2006) and may also induce IL -5 expression and eosinophil infiltration 
through the induction o f eosinophil chemoattractants (Esche et al. 2004). Increased expression o f 
IL-13 has consistently been reported in AD skin lesions and is associated with disease severit y 
(Hamid et al. 1996; Jeong et al. 2003; Tazawa et al. 2004; La Grutta et al. 2005; Neis et al. 2006; 
Choy et al.2012; Suárez-Fariñas et al. 2013). The ubiquitous presence o f IL-13 in the skin o f 
patients wi th AD supports the evaluat ion of anti -IL-13 therapies in patients with AD.
2.2.1. Clinical Manifestations of Atopic Dermatitis
Clinically, AD is characterized by  xerosis, ery thematous crusted eruption (dermatosis), 
lichenificat ion,and intense pruritus (Bieber 2008). These symptoms, along with the distribut ion, 
chronicit y, and history  of skin lesi ons, form the basis for diagnosing AD. Flares are frequent ly 
triggered by  exposure to environmental factors, irritants, and allergens (Bie ber and Novak 2009). 
Several clinical patterns, with differing distribut ions of skin lesio ns in dist inct age groups, have 
been noted (Weidinger and Novak 2016; Weidinger et al. 2018).
The infant ile stage (up to 2 y ears of age) is characterized by  eczema that is usually localized to 
the face, scalp, and extensor aspects of the arms and legs. The lesio ns are characterized by 
pruri tic, red, eczem atous pl aques, ery thema, papules, vesicles, excoriat ions, oozing, and 
formation of crusts.
The adult stage (from p ubert y onwards) i s less predi ctable than the infantile stage . Affected 
patients m ay have had only  a few outbreaks since infancy, or they  may have had a chroni c, 
relapsing course. Lesions frequent ly localize to the face and neck (head -and-neck derm atitis), as 
well in the flexures of the elbows and knees, and a considerable portion of patients develop 
atopi c hand eczema, which may  interfere wi th workpl ace act ivities. Like affected children, 
adolescents and adults commonly have lichenificatio n of the flexures and have facial dermatit is.
Patients wi th AD have a high disease burden and their qualit y of life is significant ly affected. In 
1study , AD was shown to have a greater negative effect on patient mental healt h than di abetes 
and hypertensio n (Zuberbier et al. 2006). Pati ents wi th moderate -to-severe AD have a higher 
prevalence o f social dysfunct ion and sleep impairment, which are direct ly related to the severit y 
of the di sease (Williams et al. 2008). Depression, anxiet y, and soci al dysfunct ion not only  affect 
patients wi th AD, but also affect their caregivers (Zuberbier et al. 2006). Compared with 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
25psori asis, another common and debilitat ing skin disease, patients with AD have lower physical 
vitality, soci al functi oning, rol e-emotional, and m ental  heal th scores ( Kiebert et al. 2002).
2.2.2. Treatment for Atopic Dermatitis
The therapeutic approach to AD consists primarily of trigger avoidance, skin hydration wit h 
bathing, theuse of mo isturizers ,and ant i-inflammatory  therapi es consist ing predominant ly of 
topical corti costeroids (TCS). In many  patients, treatment with TCS provides so me measure of 
symptom atic relief but does not always adequately control the disease. In those patients who 
have persistent moderate -to-severe disease not responding adequately to TCS, the step -up 
options include topical calcineurin inhibitors (TCIs), phototherapy, and immunosuppressive 
agents such as oral corticosteroids, cy closporine, azathi oprine, m ethotrexate, and mycophenolate 
mofetil. These m edicines are not available for patients across th e globe. In the US, only  
cyclosprone i s approved for treatment of moderate -to-severe AD. Recent ly, an anti-IL-4R 
monoclonal antibody that inhibits signaling for both IL -4 and IL -13,dupilumab, was approved 
for the treatm ent of  adul t and adol escent patients with moderate -to-severe AD. 
In spite of these treatments, AD remains a major societal burden and a significant unmet medical 
need.
2.2.2.1. Lebrikizumab
Lebri kizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody  (huIgG4) wi th a 
mutati on in the hinge region that increases stability. Lebrikizumab binds specifically to soluble 
human IL -13 wi th high affinit y, and potently inhibits IL -13 si gnaling through the IL -4R/IL-
13R1 com plex. Because lebri kizumab binds to IL -13 in a non -receptor binding do main (i.e., a 
porti on of  the m olecule not involved in binding to its receptor), antibody -bound IL -13 can st ill 
bind i ts receptor (IL -
13R1), but the engaged receptor complex cannot be activated.
2.3. Benefit/Risk Assessment
Atopic derm atitis remains an important pub lic health challenge. Therefore, there is a continuing 
need to develop additional treatm ent opti ons that offer alternatives to and potenti al 
improvements upon existing therapies.
Clinical benefit
The use of lebrikizumab for the treatm ent of AD is supported by numerous preclinical studies 
demonstrating that AD i s characteri zed by the increased expressio n of IL -13 in skin. Moreover, 
Phase 2 efficacy  studi es in lebrikizumab (GS29250 [TREBLE] , GS29735 [ARBAN], and 
DRM06 -AD01) demonstrated significant clinical b enefit in pat ients with AD. 
The l ebrikizumab doses and regimen planned for Study  KGAK were selected based on analyses 
of pharmacokinet ic (PK), safet y, and efficacy  data from  Phase 1 and Phase 2 studies and 
nonclinical safet y data. In addit ion, the doses a nd regimen used here are ident ical to ongoing 
Phase 3 registration trials.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
26Safety profile and mitigation plan
Blinded trial -level safet y reviews will be conducted at periodic intervals throughout the study .
An external data safet y monitoring board (DSMB) w ill conduct safet y analyses to revi ew 
unblinded safet y data. These monitoring and risk -mitigation actions, along with regular review of 
adverse events ( AEs)and laboratory data, will assist in the evaluat ion and m anagement of 
potenti al risks associated wi th lebrikizumab administrati on.
Both of the vaccines (Tdap and MCV) used in this study will be administered according to their 
approved labelling.
Additional information
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected AEs of lebrikizumab may be found in the Invest igator’s Brochure (IB).
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
273. Objectives and Endpoints
Objectives Endpoints
Co-Prim ary
To compare the seroresponses to the Tdap and 
MCV between lebrikizumab- treated and 
placebo -treated pa rticipants with 
moderate -to-severe ADThe percentage of participants who:
1.Develop a booster response to tetanus 
toxoid 4 weeks after the administration of the 
Tdap vaccine (Week 16)
Booster response is defined as:
o≥4-fold increase in anti -tetanus toxoid 
IgG antibody concentration if the pre -
vaccination level was >0.10 IU/mL and 
≤2.7 IU/mL; 
OR
o≥2-fold increase in anti -tetanus toxoid 
IgG antibody concentration if the pre-
vaccination level was >2.7 IU/mL; 
OR 
o≥4-fold increase in anti -tetanus toxoid 
IgG antibody concentration and a post -
vaccination level ≥0.10 IU/mL if the pre -
vaccination level was ≤0.10 IU/mL
2.Have positive antibody response to MCV 
(group C serum  bactericidal antibodies)
4weeks after the administration of the 
vaccine ( Week 16 )
Positive antibody response to MCV is defined 
as:
opost-vaccination hSBA titer ≥4 times the 
LLOQ, if the pre -vaccination hSBA titer 
is less than the LLOQ;
OR
opost-vaccination hSBA titer ≥4 times the 
pre-vaccination titer, if the pre -
vaccination hSBA titer is greater than or 
equal to the LLOQ
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
28Objectives Endpoints
Secondary
To compare the efficacy of lebrikizumab with 
that of placebo in treatment of participants
with moderate -to-severe AD, as measured by:Percentage of participants at Week 16 achieving :
an IGA score of 0 or 1 and a reduction of≥2 
points from baseline
EASI -75
EASI -90
≥4-point improvement from baseline in 
Pruritus NRS score 
Percentage change from baseline to Week 16 in:
EASI
Pruritus NRS score
Change from baseline in:
Percent BSA
Sleep -Loss score
To compare the patient -reported outcomes 
between lebrikizumab- treated and 
placebo -treated participants with moderate- to-
sever e AD, as measured by :Change from baseline by visit in:
PROMIS® Anxiety measure
PROMIS® Depression measure
Exploratory
Exploratory objectives and endpoints may include the following assessments . The endpoints will be 
detailed in the SAP.
Skin Pain NRS
POEM
Abbr eviations: AD = atopic dermatitis; BSA = Body Surface Area; EASI = Eczema Area and Severity Index; 
EASI -75 = ≥75% reduction from baseline in EASI score; EASI -90 = ≥90% reduction from baseline in EASI 
score; hSBA = human complement serum bactericidal assay; IGA = Investigator Global Assessment; 
IgG=immunoglob ulin G; LLOQ = lower limit of quantitation; MCV = Meningococcal (Groups A, C, Y, and W -
135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (GlaxoSmithKline) ; NRS =Numeric Rating 
Scale ; POEM = Patient -Oriented Eczema Measure; PROMIS = Patient -Reported Outcomes Measurement 
Information System; SAP = Statistical Analysis Plan; Tdap = Diphtheria and Tetanus Toxoids and Acellular 
Pertussis Vaccine Adsorbed (Sanofi) .
Note: For distinction between the clinician -administered assessment s and patient -reported outcomes, see the 
Schedule of Activities (Section 1.3), as well as Section s8.1.2 and8.1.3 .
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
294. Study Design
4.1. Overall Design
Study  KGAK is a Phase 3, 16- week, randomized, double -blind, placebo -controlled, parallel -
group tri al. The study  will evaluate whether treatment with lebrikizumab compared wit h placebo 
affects seroresponses to non -live vaccines in patients with moderate -to-severe AD. In addit ion, 
the study  will further assess the efficacy and safet y of lebrikizumab com pared wi th placebo in 
treating this pat ient population.
Study periods
KGAK has 3study  periods:
Screening (Visit 1: ≥1 day)
Treatment (Visits 2-10: 16 weeks)
Safetyfollow-up (Visit 801: at Week 26 or approximately 12 weeks after last 
treatm ent)
See the Schedule o f Activities (SoA) (Section 1.3) for addit ional details about the study  periods 
and visit -specific assessments. A schemat ic of the study  design is presented in Section 1.2.
Visit types
Depending on the preference of the study  site or the study  parti cipant, som e of the study  visits 
may be performed eit her rem otely  or on si te. 
Remote vi sits may be conducted as fo llows:
virtually (i.e., via telephone or telemedicine tools ),and
at a mobile locat ion (e.g., a participant’s ho me), if permitted by  local laws and 
regul ations.
See the table below for details about the visit ty pes.
Study visit Study week Visit type
1 -4 On site o nly
2 Baseline On site o nly
3 2 Rem ote or on site
4 4 On site o nly
5 6 Rem ote or on site
6 8 Rem ote or on site
7 10 Rem ote or on site
8 12 On site o nly
9 14 Rem ote or on site
10/early  termination (ET ) 16 On site o nly
801 Week 26 (or approximately 
12 weeks after last treatment)Rem ote or on site
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
30Treatment groups
Parti cipants found to be eligible according to all of the study  entry cri teria will be rando mly 
assigned in a 1:1 ratio to receive either lebrikizumab or placebo (see Secti on 6.1for dose and 
administration details).
Parti cipants will be stratified at randomizat ion according to their disease severit y (i.e.,IGA score 
of 3 vs 4). If the stu dy is conducted in mult iple countries , parti cipants will also be stratified 
according to the geographica l region.
Vaccine products
All participants will receive 2 vaccine inject ions at Week 12. For details, see Section 6.1.2 .
Eligibility for long-term extension study
Parti cipants who com plete thi s 16- week study  will be eligible to conti nue to a separate long -term 
extensio n study  (DRM06- AD07 /J2T-DM-KGAA ). For “completionof study ”definit ion, see 
Secti on 4.4.For rescue medicat ions allowed at entry into the long -term extensi on study , see 
Secti on 6.5.3 .
4.2. Scientific Rationale for Study Design
Vaccine types and timing of vaccine administration
When evaluat ing a new immuno modulatory  agent for potenti al use in AD patients, i t is important 
to understand any potential effects the new treatment may have on the immune response to 
vaccines. This study  will use 2different , commo nly used vaccines (Tdap and MCV) to test the 
effect of the study  drug on both the T-independent B- cell responses and T-dependent B- cell 
responses .
Both pl acebo -and lebrikizumab -treated participants will be immunized with the 2vaccines after
12 weeks of treatment ,to allow study  drug to reach steady -state l evels .Serum  antibody  levels 
will be determined at 4 weeks fo llowing vaccinat ionto allow for a maxim alantibody  response .
Demographics collection
In thi s study , collecti on of  dem ographic informati on incl udes race and ethnicit y. The scient ific 
rationale is based on the need to assess variable response in safet y and/or efficacy based on race 
or ethnicit y. This quest ion can be answered only if all the relevant data are collected.
Safety monitoring
Safety monitoring, com plaint handling, and all AEs and serious adverse events (SAEs) will be 
collected as specified in this p rotocol .This study  will collect the safet y information to further 
characterize the safet y profile of lebrikizumab.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
314.2.1. Participant Input into Design
Throughout this protocol, the term “participant” is used to indicate an individual who participates 
in a clini cal tri al, ei ther as a reci pient of  an invest igational drug or as a control. This usage 
reflects preferences indicated by  patient advocates to more accurately reflect the role of people 
who take part in clinical trials.
No participant input was provided fo r this study  design.
4.3. Justification for Dose
The lebrikizumab dosing regimen of 500 m g loading dose at baseline and Week 2, followed by 
250 m g Q2W ,was selected based on an evaluat ion of safet y, efficacy ,and PK data from  the 
DRM06 -AD01 and DRM06 -AD03 trials. This is the same dosing and treatment regimen used in 
the ongoi ng Phase 3 studies o f lebrikizumab.
4.4. End of Study Definition
A participant is considered to have co mpleted the study  if heor she has co mpleted all required 
visitsof the study , namely :
Com plete dall required visits t hrough Week 16 and through the safety  follow-up peri od
Com plete dall required visits t hrough Week 16 and roll sinto the LTE study  (DRM06-
AD07 /J2T-DM-KGAA)
The “end of the study ”is defined as the date of the last visit or the l astscheduled procedure 
shown in the SoA for the l ast parti cipant in the study globally.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
325. Study Population
Prospective approval o f protocol  deviati ons to recruitment and enrollment criteria, also know n 
as pr otocol w aivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Participant Characteristics
[1]Are male or female partici pants from 18 to 55 years of age .
Atopic Dermatitis Characteristics
[2]Have c hronic AD (according to American Academy  of Dermatol ogy Consensus Cri teria; 
Eichenfield et al. 2014 ; Appendix 10.8) that has been present for ≥1 year before the 
screening visit (Visi t 1).
[3]Have Eczema Area and Severit y Index (EASI) score ≥16 at the baseline visit
(randomization; Visit 2) .
[4]Have Inves tigator Gl obal Assessment (IGA) score ≥3 (scal e of 0 to 4) at the baseline visit
(randomization; Visit 2).
[5]Have ≥10% Body Surface Area (BSA) of AD involvement at the baseline visit
(randomization; Visit 2).
Prior/Concomitant Therapy and Vaccinations
[6]Have a history  of inadequate response to treatment with topical medicat ions; or 
determinat ion that topical treatments are otherwise medically inadvisable .
[7]Have not received any tetanus -containing vaccine within approximately 5 y ears of 
rando mizat ion (Vi sit 2).
[8] H
ave never received a meningococcal conjugate vaccine or have received not more than 1 
prior MCV dose at l east 4 years prior to randomization (Visit 2), of a vaccine containing 1 
or more m eningococcal  serogroups (serogroups A, C, W, Y) .
Reproductive Characteristics
[9]Contraceptive use by men or women should be consistent with local regulat ions regarding 
the methods of contraception for those participat ing in clinical studies.
a.Female participants of childbearing potential: must agree to remain abstinent (refrain 
from heterosexual intercourse) or use a highly effective contraceptive method during the 
treatm ent peri od and for at l east 18 weeks after the last dose of study  drug . 
Women of non -childbearing potential (non -WOCBP) may p articipate wi thout any  
contraception requirements. For definit ionsof women of childbearing potential 
(WOCBP )and non -WOCBP , see Appendix 10.4.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
33NOTE : The following are highly effect ive contraceptive methods: 
combined (estrogen and progestogen containing) hormonal contraception (oral, 
intravaginal, transdermal) associated with inhibit ion of ovulation
progestogen -only hormonal contracepti on (oral , injectable, implanta ble) associ ated 
with inhibit ion of ovulation
intrauterine device (IUD)
intrauterine hormone -releasing system  (IUS)
bilateral  tubal  occl usionand bilateral  tubal  ligat ion
vasectomized partner, or
sexual abstinence.
The reliabilit y of sexual abst inence should be evaluated in relat ion to the duration of the 
clinical trial and the preferred and usual lifest yle of the partici pant. Periodic abst inence 
(e.g., calendar, ovulat ion, symptothermal, or postovulat ion methods) an d withdrawal  are 
not acceptable methods of contraception.
b.Male parti cipants are not required to use any  contracepti on except in com pliance wi th 
specific local government study  requi rements.
Informed Consent
[10]Are c apable of giving signed informed conse nt as described in Appendix 10.1,which 
includes compliance with the requirements and restrictions listed in the informed consent 
form (ICF) and in this protocol .
Other
[11]Parti cipants m ust be willing and able to comply  with all study visits and study -related 
procedures and questionnaires.
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
[12]Have a history  of anaphylaxis, as defined by the Sampson criteria (Sam pson et al. 2006).
[
13]Have an u ncontrolled chronic disease that might require mult iple intermittent uses of oral 
corticosteroi ds, e.g., co -morbid severe uncontrolled asthma ( as defined by the invest igator ).
[14]Have an active chronic or acute infect ion requiring treatment with systemic ant ibiotics, 
antivirals, ant iparasit ics, ant iprotoxoals, or antifungals within 2 weeks before the baseline 
visit (rando mizat ion; Visit 2), or superficia l skin infect ions wit hin 1 week before the 
baseline visit. 
NOTE: Participants may be rescreened after infectio n reso lves(Secti on 5.4.1 ).
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
34[15]Have had any  of the following t ypes o f infect ion wit hin 3 mo nths of screening or develop 
any of these infect ions before rando mizat ion (Vi sit 2):
Serious (requi ring hospi talizat ion, and/or intravenous or equivalent oral ant ibiotic 
treatm ent)
Opportuni stic (as defined in Wint hrop et al . 2015) 
NOTE : Herpes zoster is considered act ive and ongoing unt il all vesicles are dry  and 
crusted over.
Chronic (duration of symptoms, signs, and/or treatment of 6 weeks or longer) 
Recurring (including, but not limited to herpes simplex, herpes zoster, recurring 
cellulit is, chronic osteomyelit is) 
NOTE : Participants with only recurrent, mild and unco mplicated orolabial and/or genital 
herpes may be discussed with the sponsor’s medical monitor to determine whether the 
participants m eet this exclus ion criterion. 
[16]Have a current or chronic infect ion with hepatitis B virus (HBV) (Section 8.2.5 ).
[17]Have a current infection wit h hepatit is C virus (HCV) (i.e., posi tive for HCV RNA ; 
Secti on8.2.6 )
.
[18]Have known liver cirrhosis and/or chronic hepat itis of any et iology.
[
19]Are d iagnosed with active endoparasit ic infect ions or at high risk of these infect ions.
[20]Have a known or suspected history  of immunosuppressio n, including history  of invasive 
opportunist ic infect ions (e.g., tuberculosis [TB], histoplasmosis, listeriosis, 
coccidio idomycosis, pneumocystosis, and aspergillosis) despite infect ion resolut ion;or 
unusually frequent, recurrent, or prolonged infect ions, per the invest igator’s judgement.
[21]Have a history  of human immunodeficiency  virus (HIV) infect ion or positive HIV serology  
at screening (Visi t 1)
.
[22]Have p resence of skin co morbidities that m ay interfere with study  assessments.
[
23]Have a h istory  of malignancy, including mycosis fungoides, within 5 y ears before screening 
(Visit 1), except completely treated in situ carcinoma of the cervix or completely  treated and 
resolved non -metastatic squamous or basal cell carcino ma of the skin with no evi dence of 
recurrence in the past 12 weeks .
[24]Have a severe conco mitant illness(es) that in the investigator ’s judgement would adversely 
affect the patie nt’s parti cipat ion in the study . Have a ny other medical or psy chological 
condi tion that in the opinio n of the invest igator may suggest a new and/or insufficient ly 
understood disease, may present an unreasonable risk to the study  participant because of 
his/her participat ion in this clinical trial, may make patient ’s parti cipat ion unreliable, or may 
interfere wi th study  assessments.
[25]Have a prior history  of Guillain -Barre syndro me.
[
26]Are allergic to latex.
[27]Have a history  of past va ccinat ion allergy or Arthus -type hypersensi tivity.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
35[28]Have an uncontrolled seizure disorder.
[29]Have known hypogammaglo bulinemia or a screening serum immunoglobulin G (IgG) or 
immunogl obulin A (IgA) concentration less than the lower limit of the report ing 
laboratory’s reference range.
Prior/Concomitant Therapy and Vaccines
[30]Have been treated with TCS, calcineurin inhibitors ,or phosphodiesterase -4 inhibitors such 
as cri saborol e within 1 week prior to the baseline visit (rando mizat ion; Visit
2).
[
31]Have been treated with any  of the f ollowing agents within 4 weeks prior to the baseline visit
(randomization; Visit 2):
a.Immunosuppressive/immuno modulating drugs (e.g. ,systemic corti costeroi ds, 
cyclosporine, mycophenol ate-mofetil, interferon gamma( IFN-γ
), Janus kinase inhibitors, 
azathi oprine, m ethotrexate, etc.)
b.Phototherapy  and photochem otherapy  (PUVA) for AD
[32]Have been treated with the fo llowing pri or to the baseline visit (randomization; Visit 2):
a.An invest igational drug within 8 weeks or within 5 half-lives (if known), whichever is 
longer
b.B Cell -deplet ing bio logics, including rituximab, within 6 months
c.Other bio logics wi thin 5 half -lives (if known) or 8 weeks, whichever is longer
[33]Have used prescri ption moisturizers within 7 days of the baselin e visi t (rando mizat ion; 
Visit 2).
[34]Have regularly used (more than 2 visit s per week) a tanning booth or parlor within 4 weeks 
of the screening visit (Visit 1).
[35]Have received a Bacillus Calmette -Guerin (BCG) vaccination or treatment within 12 months 
of screening (Vi sit 1), or have been treated with a live (attenuated) vaccine wit hin 12 weeks 
of the baseline visit (rando mizat ion; Visit 2) or planned during the study .
[36]Have a contraindication to the Tdap vaccine or MCV .
Diagnostic Assessments
[
37]In the invest igator’s opinio n, have any clinically  significant l aboratory  resul ts from the 
chemistry , hematol ogy, or urinalysis tests ob tained at the screening visit (Visit 1).
Prior/Concurrent Clinical Study Experience
[38]Have received a dose of lebrikizumab in a nyprior lebrikizumab clinical study .
[39]Are current ly enrolled in any other clinical study  involving an invest igational product or any  
other ty pe of medical research judged not to be scient ifically or medically co mpat ible with 
this stud y.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
36Other Exclusions
[40]Are pregnant or breastfeeding wo men, or women planning to become pregnant or breastfeed 
during the study .
[
41] A re invest igator site personnel directly affiliated wit h this study  and/or thei r immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological  or legally  adopted .
[42]Are emplo yees of Eli Lilly  and Com pany (Lilly ) or are emplo yees o f athird-party  involved 
in study  thatrequire sexclusion of their empl oyees.
5.3. Lifestyle Considerat ions
All study  parti cipants shoul d be instructed not to donate blood or blood products as fo llows:
within 2 to 4 weeks of study  entry
during the study ,and
forat least 18 weeks after the l ast dose of the study drug. 
No other lifest yle considerat ions are applicable to this study .
5.4. Screen Failures
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequently randomly  assigned to study  drug. 
A minimal set of screen failure informat ion is 
requi red to ensure transparent reporting of screen failure participant s to m eet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries 
from regulatory  authori ties. Minimal information includes demography, screen failure details, 
eligibilit y criteria, and any SAE.
5.4.1. Rescreening for Individuals Who Failed Screening 
Informed consent for rescreenings
Individuals who are to be rescreened must first sign a new ICF (Appendix 10.1, Secti on10.1.3 ). 
Such individuals will be assigned a new participant number.
Rescreening after failur e to meet study entry criteria
An individual who does not meet the criteria for participation in this study due to deviat ion from
the exclusio n criterion[14] (acute infect ion requiring treatment) may be rescreened one time
after the reason for the screen failure has resolved and if the sponsor has approved the 
rescreening. 
An individual who does not meet the criteria for participation in this study for other reasons may 
be rescreened one time if the reason for the screen failure has reso lved and if the sp onsor has 
approved the rescreening. 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
37Rescreening for administrative reasons
An individual may be rescreened one time for an administrative reason, including, for example, 
but not limited to, falling out of the screening window because of scheduling conflic ts. The 
sponsor does not need to approve rescreening for an administrative reason. The rescreening can 
start immediately after the administrative reason has resolved.
Procedures to be repeated at rescreening
When rescreening, all of the screening tests and procedures should be repeated.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
386. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to /used by a study  parti cipant 
according to the study  protocol .
In thi s protocol , the collect ive term “study intervention” applies both to the study drug 
(lebrikizumab or pl acebo; Sect ion 6.1.1 ) and the vaccine products (Section 6.1.2 ).
6.1. Study Interventions Administered
6.1.1. St udy Drugs
This study  involves administration of lebrikizumab andplacebo, as shown:
Study Drug Name Lebrikizumab Placebob
Dosage Formulation 250 mg (2 mL)aTo match lebrikizumab
Dosage Levels and 
FrequencyBaseline and Week 2: 500 mg loading dose
Week s 4-14: 250 mg Q2WTo match lebrikizumab
Routes of 
Administrationsubcutaneous injection subcutaneous injection
Abbreviation : baseline = randomization (Visit 2); Q2W = once every 2 weeks .
a All study drug (lebrikizumab and placebo) will be supplied as a sterile prefilled syringe with needle safety device 
(PFS -NSD). Each prefilled syringe is intended for a single 2 mL dose (250 mg) administered subcutaneously.
bPlacebo solution is identical in appearance and content to the active solution except for lebrikizumab.
For drug administration information, see Sect ions6.1.3 and 6.1.4 .
6.1.2. Vaccine Products
At Week 12, a fter the pre -dose vaccine t iters have been drawn, one dose of each of the 2 
commercially  available vaccines will be administered to all pa rticipants still on study  drug :
Tdap
MCV
Parti cipants whose study  drug has been permanently  discontinued before Week 12 will not 
receive the vaccines (Sect ion 7.1.2 ).
Vaccine administration
Vaccine inject ionswill be given per local vaccinat ion guidelines and practices and :
shoul d not be administered at sites wi th active AD or other skin lesio ns
shoul d be injected in a location different from that for the study  drug administration 
(Secti on 6.1.3 ).
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
396.1.3. Instructions for Administration in the Clinic
Study  drug and vaccines will be administered to all study  parti cipants in the clinic by designated 
and trained site staff as specified in the SoA (unless the study  parti cipant has opted for at-home 
administration of the study  drug ; see the SoA and Secti on 6.1.4 ).Detailed instructions for study  
drug administration will be provided by the sponsor.
At Week 12, the study  drug shoul d be injected in a locat ion different fro m that for vaccine 
administration.
6.1.4. Instructions for Administration at Home
During remote visits, study  participants may opt to self -administer the study  drug or have the 
mobile ho me healt h care provi deradminister i t, if permitted by  local laws and regul ations.
Parti cipants may  also opt to have their caregivers administer th e study  drug .Prior to at-home 
administration , parti cipants and /orcaregivers willbe adequately trained on the study  drug
administration at the clinical site (as indicated in the SoA, Section 1.3).
Participantsand/or theircaregiver will be instructed on the proper i njecti on technique ,and the 
participant or thei r caregiver will demo nstrate theproper inject ion technique prior to beginning 
at-home administration. 
Instructions for Use with details o f the inject ion procedures , as well as storage and handling of 
syringes, will be provided to the participant and/or thei r caregiver to take hom e. Pa rticipants who 
are not capable of administering study  drug at home (or do not have a caregiver to administer the 
drug at hom e), or who prefer not to do so, may continue to receive study  drug inject ions in the 
clinic.
Any time the study  drug is administered at hom e, participants will enter the details about the
inject ions in the electroni c patient di ary (see the SoA for details) .
6.1.5. Packaging and Labeling
Lebri kizumab and placebo will be supplied by the sponsor or its designee in accordance wit h 
current Good Manufacturing Practice (cGMP). Vaccines will be sourced as directed by the 
sponsor or its designee. Clinical trial materials will be labeled according to the country’s 
regul atory requi rements. All  study  intervent ionswill be stored, inventori ed, reconciled, and 
destroy ed according to applicable regulations (see also Section 6.2).
Each prefilled syringe with needle safet y device ( PFS-NSD )will be packaged in a carton.
6.2. Preparation/Handling/Storage/Accountability
The Pharmacy Manual provides general  instructi ons for the handling and storage of the study  
drug, as well as the site responsibilit y and accountabilit y for the administered products.
Addit ional tri al-specific information is provided in other docum ents (see Secti ons 6.1.3 and 
6.1.4 ). For storage information for lebrikizumab, refer to the investigational product label.
For vaccine- related inform ation, refer to the local labels and guidelines.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
40Site responsibili ties and accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion rece ived and any discrepancies are 
reported and resolved before use of the study  intervent ion.
Only participants enro lled in the study  may receive study  intervent ion and only personnel  
authori zed by the primary  invest igator or by the sponsor may supply or admi nister study  
intervent ion. All study  interventi on must be stored in a secure, environmentally 
controlled, and monitored (manual or automated) area in accordance with the labeled 
storage condit ions wit h access limited to the investigator and authorized site staff (unless 
the study  drug will be administered at home by the participant or caregiver) .At-home 
storage instructions are provided in the pa rticipant s’ Instruc tions f or Use.
The invest igator, institution, or the head of the medical inst itution (where a pplicable) i s 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance 
(i.e., recei pt, reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  interventi ons
are provided in the Pharm acyManual .
6.3. Measures to Minimize Bias: Randomization and Blinding
This is a double -blind study . The sponsor or desi gnee, the invest igator, study- site personnel, and 
the participant will be blinded to treatment assignment. The integrit y of the clinical study  will be 
maintained by  observing the treatm ent blind.
Method of treatment assignment
The rando mizat ion rati o and stratificat ion factors are described in Sect ion 4.1.
Assignment to treatment groups will be determined by a co mputer -generated random sequence 
using an interactive web -response system (IWRS). Each study  partici pant will be assigned a 
unique identificat ion number.
Emergency unblinding
Emergency  unblinding for AEs may be perform ed through the IWRS. This option may be used 
ONLY if the part icipant’s well -being requires knowledge o f the participant’s treatment 
assignment . All actions result ing in an unblinding event are recorded and reported by  the IWRS.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a parti cipant ’s study  drug assignment is warranted. Participant saf ety must always be the first 
consideration in making such a determinat ion. If the invest igator decides that unblinding is 
warranted, it is the responsibilit y of the invest igator to prompt ly document the decisio n and 
rationale and notify the sponsor as soon as possible.
Unblinding and participant discontinuation
See Secti on 7.2.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
416.4. Study Intervention Compliance
Parti cipants will receive study  intervent ion directly fro m the invest igator or designee, under 
medical supervisio nunless they  opt for at-home administration of the study  drug by  themselves 
or thei r caregivers (see Section 6.1.4 ).
When administered in the clinic , the date and time of each dose will be recorded in the source 
docum ents and recorded in the electroni c case report form ( eCRF ).When administered at home, 
participants will enter the details about the study drug inject ions in the electronic patient diary 
(see the S oAfor details).
A participant will be considered compliant with the dosing regimen if the participant received 
80% of the expected number of study  drug inject ions while enrolled in the study .
6.5. Concomitant Therapy
All medications (including over -the-counter drugs, vitamins, and antacids ) and over- the
-counter 
emollient(s) taken/used at screening and throughout the study  must be recorded. Participants
shoul d be instructed to consult with the invest igator prior to init iating any new medicat ion (either 
self-administered non -prescri ption drugs or prescription therapy  prescribed by another physician) 
while participat ing in the study . The invest igator is expected to examine the acceptabilit y of all 
concomitant medicat ions, topical preparations, and dietary  supplements taken by  the study  
participants .
Medicat ion entri es shoul d be specific to product name (if a combinat ion drug product) 
and spelled correctly . 
The brand and specific product name for any  over -the-counter emo llient(s) should be 
noted and spelled correctly.
Inform ation on the dose, un it, frequency , route of administrati on, start date, 
discontinuat ion date, indicat ion, and reason for use will be recorded. 
The use of any  concomi tant m edicat ion must rel ate to an AE listed on the AE eCRF or 
the participant ’s medical history  unless i t is asupplement or used as preventative care.
6.5.1. Permitted and Prohibited Treatments and Procedures
Permitted medications
The use of conco mitant m edicat ions for other medical condit ions (e.g., hy pertensi on, diabetes, 
acute infect ions) is permitted during this stu dy. Inhal ed corticosteroi ds and bronchodilators to 
control  asthma are permitted.
In addit ion, TCS or TCI may be used during the study  (low-or mid -potency only). 
Participants may use TCS (described below) for AD symptoms starting at the baseline visit 
(randomization: Visit 2/Day 1).
Participants may taper or stop TCS use, as needed. If AD lesions return or a participant
experiences a flare, TCS treatment may be resumed at the participant ’s discretion.
Low-potency TCS or TCIs may be used for sensit ive areas only  (i.e., face, neck, intertriginous, 
and genital areas).
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
42Parti cipants may  use the following TCS, if needed :
a mid-potency  TCS: triamcino lone acetonide cream 0.1%, and
a low-potency TCS: hydrocortisone 1% cream (for use on sensit ive skin areas, e.g., face).
All TCS use should be recorded in the eCRF.
Prohibited medications and procedures
The introduction of medications or therapies for other medical condit ions known to aff ect AD 
(e.g., systemic corticosteroids, mycopheno late-mofetil, IFN -
y, Janus kinase inhibitors, 
cyclosporine, azathioprine, methotrexate, phototherapy  or photochemotherapy , or 
phosphodiesterase -4 inhibitors such as crisaborol e) are not permitted during the study . 
The use of systemic corticosteroids for the treatment of AD is prohibited and requires permanent 
discontinuat ion of study  drug (Secti on 7.1.2 ).If used for tr eatment of AEs (for example, 
worsening of exist ing condit ion, such as asthma exacerbat ion), it will  be treated as rescue 
medicat ion as per the Section 6.5.3 .
Acute severe infect ions can be treated with systemic ant ibiotics, use of which must be recorded 
in the eCRF. However, chronic treatment with systemic ant ibiotics is not permitted. 
The use of a tanning booth/parlor is not permitted during the trial.
Cannabino id treatments for AD are prohibited.
Planned or anti cipated major medical procedures or surgeries should be avo ided during the trial. 
See Secti on 6.5.3 for details on approved rescue medicat ions and t iming o f use.
6.5.2. Background Treatment: Non -Medicated Moisturizers
Participants are to apply a stable dose of non -medicated topical mo isturi zer at l east twi ce daily 
for ≥7 day s prior to the baseline visit.
Non-medicated m oisturi zers are to be used during the study . The participants may continue their
current over -the-counter m oisturi zer regimen, if approved by  the invest igator.
All moisturi zer use shoul d be recorded i n the eCRF.
6.5.3. Rescue Treatment for Atopic Dermatitis
During this study , add -on rescue therapies may  be needed if the participant experiences clinical 
worsening of symptoms that are intolerable.
Parti cipants will be eligible to receive rescue treatm ent wi th any l ocally  approved ADtreatm ents 
at the discretion of the invest igator. Invest igators are encouraged to provide rescue therapy in a 
staged fashion, using a greater intensit y of treatm ent com pared to that which the participant was 
using, for exam ple:
high-potency  TCS, or
treating with :
ooral corti costeroi ds
osystemic nonsteroid immunosuppressants, or
ophototherapy . 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
43Refer to Section 7.1.2 for discont inuat ion criteria associ ated wi th systemic rescue treatment.
Participants using topical or systemic rescue medication who complete the study  through 
Week 16 will be eligible to continue to a separate long -term extensio n study  after the Week 16 
visit has been co mpleted.
All rescue treatment usage must be captured in the eCRF.
6.6. Dose Modification
Dose m odificat ions of lebrikizumab are not allowed in this study .
6.7. Intervention after the End of the Study
Parti cipants who com plete Study  KGAK through Week 16 will be assessed for eligibilit y to enter 
a separate long- term extensio n study  (DRM06- AD07/J2T -DM-KGAA). If a participant does not 
meet enrollment criteria for the long -term extensio n study  or does not opt to continue into that 
study , he or she will be asked to complete the post -treatm entfollow-up peri od as described in the 
SoA (Section 1.3), which will co mplete his or her study  participati on.
Lebri kizumab will  not be available to the KGAK study participants unless they  enter the l ong-
term extensio n study .
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
447. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
The sections below describe reasons for a participant’s :
temporary  or perm anent discont inuat ion of study  drug (Secti on 7.1), or
discontinuat ion (wi thdrawal) from  the st udy (Section 7.2).
Discontinuati on of  specific sites or the trial as a who le is handled as part of regulatory , ethi cal, 
and tri al oversight considerat ions in Appendi x 10.1, Secti on 10.1.9 .
7.1. Discontinuation of Study Intervention
Study  drug m ay be perm anently discont inued or temporarily wit hheld during the study .
7.1.1. Criteria for Temporary Discontinuation of Study Drug
Cases that m ay merit tem porary  withhol ding of the study  drug shoul d be discussed with the 
medical mo nitor.The medical mo nitor, in consultation with the invest igator, will determine 
when it i s appropri ate to recommence study  drug.
Parti cipants who require a tem porary  withholding of study  drug after Week 6 will not receive the 
Tdap and MCV vaccinat ions at Week 12 unless approved by the medical mo nitor.
Parti cipants who require a temporary  withholding of study  drug will not be eligible for entry  into 
the long-term extensio n study  unless they cont inue to complete study visits and assessments 
through Week 16 .
Some possible reasons for temporarily wit hholding the study  drug include, but are not limited to:
Seriousor opportunist ic infect ions(Secti on5.2and Appendix 10.7). Study  drug is to be 
withheld unt il reso lution of all acute clinical signs and symptoms, and complet ion of all 
appropriate anti -infective treatment.
Hepati tis Bvirus DNA results that are reported as posit ive, or as detecting HBV DNA, 
but HBV DNA is below the level o f quant ificat ion:The sponsor’s designated medical 
monitor shoul d be contacted regarding study  status of the participant. H epatit is Bvirus
DNA testing is to be repeated as soon as is feasible. If HBV DNA is confirmed as 
positive, the parti cipant m ust be perm anently discont inued fro m study  drug 
(Section7.1.2 ).
Hepati c event or liver test abnormalit y:The study  drug should be wit hheld and addit ional 
testing performed fo llowing consultat ion with the Lilly -designated m edical m onitor, if 
the resul ts of repeat tests following elevated alanine aminotransferase ( ALT ), alkaline 
phosphatase (ALP)or total  bilirubin level (TBL) include one of the following 
(Secti on8.2.7 ):
oALT 3x upper limit o f norm al (ULN )and TBL <2x ULN
oALP 2x ULN and TBL <2x ULN
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
45oTBL 2x ULN wi thout increase from  baseline in ALT/aspartate aminotransferase 
(AST )/ALP.
7.1.2. Criteria for Permanent Discontinuation of Study Drug
In rare instances, it may be necessary  for a parti cipant to perm anent ly discont inue (definit ively 
discontinue) study  drug.
Possible reasons for permanent discontinuation of study intervention
Possible reasons that may lead to permanent disco ntinuat ion of the study  drug include, but are 
not limited to, the following:
Investigator decision
The invest igator decides that the participant shoul d be discontinued from study  
drug.Some examples may include:
oInter -current illness that would, in the jud gment of the invest igator, affect 
assessments of clinical status to a significant degree
oTreatment -related AEs that are clinically significant, deemed persistent, in the 
judgment of the investigator
oUnacceptable toxicit y
Systemic hypersensitivity reaction
If the invest igator, after consultation with the sponsor -designated medical 
monitor, determines that a sy stemic hypersensit ivity reacti on has occurred rel ated 
to study  drug administration, the participant should be permanent ly discont inued 
from the study  drug.
If a parti cipant experiences a hypersensit ivity event determined by  the 
investigator to relate to the vaccine products, the participant will not be 
perm anent ly discont inued fro m the study  drug.
Required reasons for permanent discontinuation of study i ntervention
Perm anent discont inuat ion of study  drug should occur in the fo llowing instances:
Use of systemic rescue treatment
If a participant receives rescue treatment with a systemic corticosteroid, 
immunosuppressant, or phototherapy , the parti cipant must perm anent ly discont inue study  
drug.
Parti cipants who receive rescue treatment with topical steroids may  cont inue treatment 
with study  drug.
NOTE: Participants who discont inue study  drug due to rescue medication use shoul d 
continue to attend all study  visitsthrough Week 16 and be assessed for safet y and 
efficacy  according to the SoA (as shown in the table at the end of this subsection ).
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
46Hepatic event or liver test abnormality
Parti cipants who are di scont inued fro m the study  drug due to a hepatic event 
or liver test abnormalit y shoul d have addit ional hepati c safet y data collected 
via eCRF. Discont inuat ion of the study  drug for abnorm al liver tests should 
beconsidered by the invest igator when a participant meets one of the 
following condit ions after consultation with the sponsor -designated medical 
monitor (see Secti on8.2.7 ):
oALT or AST ≥8 times ULN
oALT or AST ≥5 times ULN for more than 2 weeks
oALT or AST ≥3 times ULN and TBL ≥2 times ULN or international normalized 
ratio (INR) ≥1.5 
oALT or AST ≥3 times ULN wit h the appearance of fat igue, nausea, vo miting, 
right upper -quadrant abdominal pain or tenderness, fever, and/or rash
oALP ≥3 times ULN
oALP ≥2.5 times ULN and TBL ≥2 times ULN, or 
oALP ≥2.5 times ULN with the appearance of fatigue, nausea, vo miting, right 
upper quadrant abdominal pain or tenderness, fever, and/or rash
Other laboratory findings
Total  white blood cell (WBC) count <2000 cells/L (<2.00 x 10 3/µL or 
<2.00 GI/L)
Lymphocy te count <500 cells/μL (<0.50 x 10 3/µL or <0.50 GI/L)
Platelet coun t <50,000 cells/μL (<50 x 10 3/µL or <50 GI/L)
Other safety considerations
The parti cipant develops any  of the f ollowing condit ions during the study :
oMalignancy (except for successfully treated basal or squamous cell skin 
carcino ma)
oSerious or opportunistic infection that in the opinio n of the investigator merits 
the study  drug being discontinued. Such infect ions may include, but are not 
limited to:
HIV/acquired immune deficiency syndrome (AIDS) infect ion
active TB infect ion or un treated latent TBinfect ion (LTBI )
HCV RNA posit ive (Sect ion 8.2.6 )
HBV DNA posit ive (Section 8.2.5 )
NOTE : The HBV DNA result is to be confirmed if init ial posi tive tes t 
resul t is posi tive but below the level o f quant ificat ion (Section 7.1.1 ; 
Secti on8.2.5 ). The participant is to be referred to, evaluated, and managed 
by a specialist physician wit h expertise in evaluat ion and management of 
viral hepat itis prior to discontinuation of any immuno modulatory  and/or 
immunosuppressive therapy , includi ng study  drug. Timing of 
discontinuat ion from study  drug rel ative to the init iation of any ant iviral 
treatm ent for hepati tis is to be based on the recommendat ion of the 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
47consult ing specialist physician, in conjunction wit h the investigator, and 
aligned wit hmedical guidelines and standard of care.
If study  drug i s definit ively discont inued, the participant will eit her remain in the study  or not, as 
follows:
If the study drug is permanently discontinued
due to systemic rescue treatment ,If the study drug is permanently 
discontinued for other reasons,
then participants stay  in the study  to:
complete all the remaining study  visit s and 
assessments through Week 16
AND
roll into the long-term extensi on study , if 
entry  criteria are m et
OR
undergo the safet y follow-up visit (V801).then participants will not stay in the 
study  and
undergo an ET visit
AND
the safety  follow-up visi t (V801).
If the study  drug is perm anent ly discont inued before Week 12 and participants are continuing in 
the study , these study  parti cipants will not receive the vaccines at Week 12.
See the SoA for assessments to be performed at the time of the ET visit and safet y follow-up. In 
addition to the SoA, safet y follow-up is outlined in Secti on 8.2(“Safety Assessments ”) and 
Secti on 8.3(“Adverse Events and Serious Adverse Events”) of the protocol.
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study :
●at any  time at his/her own re quest 
●at the request of his/her designee (for example, legal guardian)
●at the discretion of the invest igator for safet y, behavi oral, com pliance, or 
administrative reasons
●if the participant beco mes pregnant during the study (see Secti on 8.3.5 and 
Appendix 10.4, Secti on10.4.3 )
●if enro llment in any other clinical study invo lving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study
●if the participant , for any  reason, requi res treatm ent wi th another therapeuti c agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agen t
The parti cipant m ust be di scont inued fro m the study:
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
48●if an invest igator, site personnel performing assessments, or participant is 
unblinded
NOTE : In cases where there are ethical reasons to have the participant remain in the 
study , the invest igator must obtain specific approval fro m the sponsor -designated medical 
monitorfor the participant to continue in the study .
Discontinuati on is expected to be unco mmo n.
At the time of discont inuing from the study , if possible, an ET visit should be conducted, as 
shown in the SoA. See SoA for data to be collected at the time o f study  discont inuat ion and 
follow-up and for any  further evaluat ions that need to be completed. The parti cipant will be 
perm anent ly discont inued both fro m the study  intervent ion and fro m the study  at that time.
If the participant withdraws consent for disclos ure of  future inform ation, the s ponsor m ay retain 
and cont inue to use any data co llected before such a withdrawal o f consent .If a participant
withdraws fro m the study , he/she may  request destructi on of  any sam ples taken and not tested ,
and the invest igator must document this in the site study records .
7.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ify a participant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the participant shoul d be discont inued fro m study  drug unless there 
are extenuat ing circumstances that make it medically necessary for the participant to continue on 
study  drug.If the invest igator and the sponsor -designated medical monitoragree it is medically 
appropriate to continue, the invest igator must obtain docum ented approval fro m the sponsor -
designated medical monitorto allow the inadvertent ly enro lled participant to continue in the 
study  with or wi thout treatm ent wi th the study  drug .Safet y follow up i s as outlined in 
Secti on1.3(Schedule of Act ivities), Secti on 8.2(Safet y Assessments), and Section 8.3(Adverse 
Events and Serious Adverse Events) of the protocol.
7.3. Lost to Follow up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.Site personnel are expected to 
make diligent attempts to contact participants wh o fail  to return for a scheduled visit or were 
otherwi se unable to be fo llowed up by the site.
Site personnel, or an independent third party , will  attem pt to collect the vital status of the 
participant wi thin legal  and ethical boundaries for all participants randomized, including those 
who did not get the study  drug . Public sources may  be searched f or vital status inform ation. If 
vital status i s determined to be deceased , this will  be docum ented and the participant will not be 
considered lost to fo llow-up. Sponsor personnel will not be invo lved in any attempts to collect 
vital status inform ation.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
498. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon occurrence or 
awareness to determine if the participant should cont inue or discont inue study  intervent ion.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al participant s 
meet all e ligibilit y criteria. The invest igator will maintain a screening log to record details o f all 
participant s screened and to confirm eligibilit y or record reasons for sc reening failure, as 
applicable.
8.1. Efficacy Assessments
8.1.1. Primary Outcome Measures: Vaccine Responses
Seror esponses to vaccines will be assessed as fo llows:
Tdap vaccine: a booster response as measured by tetanus toxoi d-specific IgG ant ibodies
MCV : a positive ant ibody  response to Group C serum bactericidal ant ibodies
For details about the primary  endpoints and definit ions of the booster response and positive 
antibody  response, see Sect ion 3.
For details about the laboratory  tests to support the primary outcome measure, see 
Appendix 10.2. For frequency  of these tests, see the SoA (Secti on 1.3).
8.1.2. Secondary Outcome Measures: Efficacy
Each participant ’s AD will be assessed as specified in the SoA (Secti on 1.3). Whenever possible, 
the sam e assessor should perform all assessments on a given partici pant over the course of the 
study . The sponsor will administer training on the required efficacy  assess ments ;detail  on the 
specific instruments and training given are recorded in the study  training m aterials.
All clinician -reported efficacy assessments will be captured on an electronic tablet during the site 
visitsafterall the pati ent-reported outcomes h ave been completed.
Appropriateness of assessments
All theassessments used in this study  are relevant for the AD populat ion.Some measures have 
been validated and are widely used , including the following :
EASI ( Hanifin et al. 2001)
POEM (Charman et al. 2004)
Skin Pain NRS (New ton et al. 2019; data on file)
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
508.1.2.1. Investigator Global Assessment (IGA)
The IGA is a static assessment and rates the severity o f the participant ’s AD. The IGA is 
comprised of a 5 -point scale ranging from 0 (clear) to 4 (severe) ,and a score is selected using 
descriptors that best describe the overall appearance of the lesio ns at a given time po int. It is not 
necessary  that all characteri stics under Morphological Descript ion be present. 
Assessors m ust be trained and certified by the sponsor pri or to conducting this assessment. The 
IGA m ust be conducted prior to conducting the EASI and BSA assessments. A single assessor 
shoul d be assi gned to each individual participant for as many visits as possible, to avoid inter -
assessor variabi lity in scoring.
8.1.2.2. Eczema Area and Severity Index ( EASI )
The EASI is a validated measure that evaluates 2 dimensio ns of AD: di sease extent and clinical 
signs (Hanifin et al . 2001).
The EASI assesses extent of disease at 4 body  regions and measures 4 clinica l signs , each on a 
scale of 0 to 3 : 
(1) ery thema
(2) induration/papulat ion
(3) excori ation, and 
(4) lichenificat ion.
The EASI i s a com posite index wi th scores ranging fro m 0 to 72, with the higher values 
indicat ing more severe or extensive disease. 
Assessors m ust be trained and certified by the sponsor prior to conducting this assessment.
8.1.2.3. Body Surface Area (BSA)
The BSA assessment estimates the extent of disease or skin invo lvement with respect to AD and 
is expressed as a percentage of total body  surface. BSA will be determined by the investigator or 
designee using the participant palm = 1% rule. 
Assessors m ust b e trained and certified by the sponsor pri or to conducting this assessment.
8.1.3. Patient -Reported Outcomes
The outcome measures used in this study  are rel evant to the AD populat ion.
Parti cipants will co mplete these assessments as fo llows, prior to the other study  assessments ; see 
also the SoA (Section 1.3):
Electronic diary  (com pleted at hom e):
oPruri tus NRS (daily)
oSleep-Loss (daily)
oSkin Pain NRS (daily)
oPOEM (weekly)
Electronic tablet (provided at the site): 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
51oPROMIS ®Anxiet y
oPROMIS ®Depressio n
8.1.3.1. Prurit us Numeric Rating Scale ( NRS )
Parti cipants will assess pruritus using a Pruritus NRS. The Pruritus NRS is an 11 -point scale 
used by pat ients to rate their worst itch severit y over the past 24 hours, with 0 indicating “No 
itch” and 10 indicat ing “Worst itch imaginable.”
Participants will record th e pruri tus assessments daily using an electroni c diaryat hom e. As 
indicated in the S oA(Secti on 1.3), initial electronic di ary entri es for Pruri tus NRS should be 
completed a minimum o f 4 of7 day s before randomizat ion.
8.1.3.2. Sleep -Loss
Parti cipants will assess their Sleep-Loss due to pruri tus. They  will rate thei r sleep based on a 
5-point Likert scale: 0 (not at all) to 4 (unable to sleep at all). 
Parti cipants will record their Sleep-
Loss assessments daily using an electroni c diaryat hom e. As 
indicated in the S oA(Secti on 1.
3), initial electronic di ary entri es for Sl eep-Loss should be 
completed a minimum o f 4 of7 day s before randomizat ion.
8.1.3.3. Skin Pain Numeric Rating Scale (NRS)
Skin Pain NRS (Newton et al. 2019) is a patient -administered, validated, 11-point horizontal 
scale anchored at 0 and 10, with 0 represent ing “no pain” and 10 represent ing “worst pain 
imaginable.” Overall severit y of a pati ent’s skin pain is indicated by  select ing the number that 
best describes the worst level o f skin pain in the past 24 hours .
Parti cipants will record the Skin Pain NRS assessments daily using an electronic diary at home.
As indicated in the S oA(Section 1.3), initial electroni c diary  entries for Skin Pain NRS should 
be co mpleted a minimum o f 4 of7 days before randomizat ion.
8.1.3.4. Patient -Oriented Eczema Measure (POEM)
The POEM (Charman et al. 2004) isa 7-item, validated questionnaire used by  the patientto 
assess disease symptoms over the last week. The pa tientis asked to respond to 7 questions on:
skin dryness
itching
flaking
cracking
sleep l oss
bleeding, and 
weeping. 
All 7 answers carry  equal  weight wi th a total  possible score fro m 0 to 28 (answers scored as: No 
days =0; 1‒2days = 1; 3–
4 days = 2; 5‒6 days = 3; every day = 4). A high score is indicat ive of 
a poor qualit y of life. 
Parti cipants will capture the POEM responses weekly using an electroni c diary at hom e.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
528.1.3.5. Patient -Reported Outcomes Measure ment Information System (PROMIS®): 
Anxiety and Depression 
Patient-Reported Outcomes Measurement Information System is a set of person -centered 
measures that evaluates and monitors patient’s physical, mental, and social healt h(PROMIS 
WWW) . 
The PROMIS®measures used in this study  include Anxiet y and Depressio nshort form s, which 
assess the patients’ symptoms over the previous week.
Parti cipants will co mplete the PROMIS measures on an electronic tablet on site (see the SoA for 
frequency; Sect ion 1.3).
PROMIS®Anxiety
This tri al uses the PROMIS Short Form v1.0 –Anxiet y -8a.The PROMIS®Anxiety short form  
assesses the following items (PROMIS Anxiet y 2019):
●self-reported fear (fearfulness, panic)
●anxious misery (worry, dread)
●hyperarousal (tension, nervousness, restlessness), and
●somatic symptoms related to arousal (racing heart, dizziness). 
Each quest ion has 5 response options, with scores ranging from 1 to 5. The total scores range 
from 8 to 40, wi th the hi gher score indicat ing a higher level o f anxiet y.
PROMIS®Depression
This tri al uses PROMIS Short Form  v1.0 – Depression 8b . The PROMIS®Depressio n short form
assess es the following items (PROMIS Depressio n 
2019):
●self-reported negative mood (sadness, guilt)
●views of self (self -criticism, worthl essness)
●social cognit ion (loneliness, interpersonal alienation), and
●decreased positive affect and engagement (loss of interest, meaning, and purpose). 
Somatic symptoms ( such as changes in appetite or sleeping patterns) are not included . Thi s helps 
eliminate potential confounding effects of these i tems when assessing participants with com orbid 
physical condit ions.
Each quest ion has 5 response options, with scores ranging from 1 to 5. The total scores range 
from 8 to 40, wi th the hi gher score indicat ing a higher level o f depressio n.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
538.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA (Section 1.3).
8.2.1. Physical Examinations
A co mplete physical examinat ion will cover general appearance and the following body  parts 
and systems:
derm atological
head
ears
eyes
nose
throat
respi ratory
cardi ovascular
abdo minal
neuro logical
musculoskeletal, and
lymphat ic.
Height and wei ght will  also be recorded. 
At subsequent study  visits, a symptom -directed physical examinat ion may be conducted at the 
discreti on of  the invest igator. Findings will be recorded as medical history or AE in the eCRF.
8.2.2. Vital Signs
Vital signs, including body  temperature, respi ratory  rate (breath sper minute), pulse (beats per 
minute), and blood pressure (mmHg), will be obtained wit h the participant in the seated position, 
after si tting for at l east 5 minutes. Any  abnorm al findings thatare new or worsened in severit y 
and clinically  signi ficant, in the opinio n of the investigator, will be recorded as an AE. Vital sign 
measurements will be recorded in the eCRF.
8.2.3. Clinical Safety Laboratory Assessments
See Appendix 10.2 for the list of clinical laboratory  tests to be perform ed and to the So A for the 
timing and frequency .
Review ing and recording test results
The invest igator must review the laboratory report, docum ent thi s review, and record any  
clinically relevant changes occurring during the study  in the AE section of the eCRF. The 
laboratory  reports m ust be filed wit h the source documents. Clinically significant abnormal 
laboratory  findings are those which a re not associ ated wi th the underlying disease, unless judged 
by the investigator to be more severe than expected for the participant ’s condi tion.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
54Repeat testing after clinically significant abnormal findings
All laboratory  tests wi th values considered clin ically significantly abnormal during 
participat ion in the study or within 28 days after the l ast dose of study  interventi on shoul d 
be repeated until the values return to normal or baseline or are no longer considered 
clinically significant by  the investi gator or m edical m onitor.
If such values do not return to normal/baseline wit hin a peri od of  time judged 
reasonable by the invest igator, the etio logy shoul d be ident ified and the sponsor 
notified.
All protocol -requi red laboratory  assessments, as defined in A ppendix 10.2, must 
be conducted in accordance with the laboratory  manual and the SoA.
If laboratory  values fro m non-protocol  specified l aboratory  assessments perform ed at the 
institution’s l ocal laboratory  requi re a change in parti cipant m anagement or are 
considered clinically significant by  the investi gator (e .g., SAE or AE or dose 
modificati on), then the clinically significant resul ts willbe reported as an AE in the AE 
sectionofthe eCRF.
Blinding of laboratory test results
Laboratory  resul ts that coul d unblind the study  will not be reported to invest igative sites or other 
blinded personnel (Appendix 10.2).
8.2.3.1. Pregnancy Testing
Pregnancy testing is to be performed on WOCBP. Parti cipants who are pregnant will be 
discontinued fro m the study (Secti on7.2).
Visits and times
Serum  pregnancy test will be done at screening only , and resul ts will be confirmed by  the central  
laboratory , as stated in Appendix 10.2.
Urine pregnancy  testing will  be perform ed locally  at visi ts specified in the SoA (Section 1.3). If 
the specified visit includes study  drug administration, the urine pregnancy  test m ust be 
“negative” within 24 hours before the study  drug is administered.
Urine pregnancy  testing may  be perf ormed at addi tional time po ints during the study  treatm ent 
period and/or fo llow-up peri od, at the di scret ion of the investigator or if this is required by local 
regul ations.
8.2.4. Systemic Hypersensitivity Reactions
Many  drugs, but parti cularly bio logic agents, carry the risk of systemic hypersensit ivity 
reacti ons. Vaccines m ay be associated with such hypersensit ivity react ions, as well. If such a 
reacti on occurs, addi tional data describing each symptom should be provided to the sponsor in 
the eCRF.
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  parti cipants are receiving the study  intervent ion. It is recommended that 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
55participants who experience a systemic hypersensit ivity react ion be treated per national and 
internat ional guidelines.
In the case of generalized urti caria or anaphylaxis, addit ional blood and urine samples shoul d be 
collected as described in Appendix 10.5. Laboratory  resul ts are provi ded to the sponsor via the 
central laboratory .
8.2.5. Hepatitis B Testing and Monitoring
Initial testing for HBV infect ion includes (CDC WWW) :
hepat itis B surface antigen (HBsAg)
hepat itis B core (anti- HBc), and 
hepat itis B surface antibody (ant i-HBs).
If … Then …
HBsAg is positive the participant is excluded.
HBsAg is negative and anti -HBs is positive 
(regardless of anti -HBc result)
OR
HBsAg, anti -HBs, and anti -HBc are all 
negativethe participant is not excluded.
anti-HBc is positive
and
HBsAg and anti -HBs are negativefurther testing for HBV DNA is required :
If the screening HBV DNA is positive, the participant is 
excluded.
If the screening HBV DNA is negative, the participant is not 
excluded. Repeat testing for HBV DNA is required at least 
every 3 mo nths during the study (Section 1.3), with 
temporary withholding or permanent discontinuation of study 
interventio n if HBV DNA is positive, as described in 
Section s7.1.1 and 7.1.2 , respectively.
Management of enrolled participants w ith detectable HBV DNA during the study
See Secti ons 7.1.1 and 7.1.2 .
8.2.6. Hepatitis C Testing and Monitoring
Initial testing for HCV infect ion includes testing for antibodies to HCV :
If ant i-HCV is posi tive, a serum test for circulat ing HCV RNA is required.
If HCV RNA test is negative, the participant is not excluded.
If HCV RNA test is posit ive, the participant is excluded (see Section 5.2).
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
56Parti cipants who have had HCV infection and been successfully  treated, defined as a sustained 
virologic response (HCV RNA by PCR negat ive for at least 24 weeks fo llowing treatment 
completion) are not excl uded on the basis of HCV as long as HCV RNA test is negat ive at 
screening.
If HCV RNA is detected during the study , the study  drug will be perm anently discont inued 
(Secti on7.1.2 ), and the participant should receive appropriate fo llow-up m edical care.
8.2.7. Hepatic Safety Monitoring
Close hepatic monitoring
The l aboratory  tests listed in Appendix 10.6, including ALT, AST, ALP, TBL, direct bilirubin , 
gamma- glutamyl  transferase (GGT), and creatine kinase (CK), should be repeated within 48 to 
72 hours, to confirm the abnormalit y and to determine whether it is increasing or decreasing, if 
these condit ions occur:
If a participant with baseline... has the following elevations:
ALT or AST <1.5 times ULN ALT or AST ≥3 times ULN
ALP <1.5 times ULN ALP ≥2 times ULN
TBL <1.5 times ULN TBL ≥2 times ULN
ALT or AST ≥1.5 times ULN ALT or AST ≥2 times baseline
ALP ≥1.5 times ULN ALP ≥2 times baseline
TBL ≥1.5x ULN TBL ≥2x baseline (except for patients with Gilbert’s 
syndrome)
If the abnormalit y persists or worsens, clinical and laboratory  monitoring, and evaluat ion for the 
possible causes of the abnormal liver tests should be init iated by  the investi gator i n consul tation 
with the sponsor’s designated medical mo nitor.At a minimum, this evaluat ion shoul d include a 
physical examinat ion and a thorough medical history , including symptoms, recent illnesses (for 
example, heart failure, systemic infection, hypotension, or seizures), recent travel, history o f 
concomitant medicat ions (including over -the-counter), herbal and dietary  supplements, history  of 
alcoho l drinking, and other s ubstance abuse.
Initially, m onitoring of  symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the parti cipant’s clinical condit ion and hepat ic biochemical tests.
Subsequently, the frequency  of monitoring m aybe lowered to once every  1 to 2 weeks, if the 
participant’s clinical condit ion and l ab resul ts stabilize. Moni toring of ALT, AST, ALP ,and 
TBL should cont inue unt il levels normalize or return to approximate baseline levels.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
57Comprehensive hepatic evaluatio n
A co mprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
these condit ions occur:
If a participant with baseline... has the following elevations:
ALT or AST <1.5 times ULN ALT or AST ≥3 times ULN with hepatic signs/symptoms*, or
ALT or AST ≥5 times ULN
ALP <1.5 times ULN ALP ≥3 times ULN
TBL <1.5 times ULN TBL ≥2 times ULN
ALT or AST ≥1.5 times ULN ALT or AST ≥2 times baseline with hepatic signs/symptoms*, or
ALT or AST ≥3 times baseline
ALP ≥1.5 times ULN ALP ≥2 times baseline
TBL ≥1.5x ULN TBL ≥1.5x baseline (except for patients with Gilbert’s syndrome)
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, 
fever, and/or rash.
At a minimum, this evaluat ion should include a physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for prothrombin t ime INR (PT-INR); viral hepat itis A, 
B, C, and E; tests for autoimmune hepat itis, and an a bdominal imaging study  (for example, 
ultrasound or CT scan).
Based on the participant’s history  and ini tial resul ts, further testing should be considered in 
consultation wit h the sponsor’s designated medical monitor, including tests for hepatit is D virus 
(HDV), cy tomegalovirus (CMV), Epstein -Barr vi rus (EBV), acetaminophen levels, 
acetaminophen protein adducts, urine toxico logy screen, Wilso n’s disease, blood alcoho l levels, 
urinary  ethylglucuroni de, and serum  phosphati dylethano l.
Based on the circumstances and the investigator’s assessment of the participant’s clinical 
condi tion, the invest igator should consider referring the participant for a hepatologist/ 
gastroenterologist consultation, magnet ic resonance cho langiopancreatography  (MRCP), 
endoscopi c retro grade cholangiopancreatography (ERCP), cardiac echocardiogram, or a liver 
biopsy.
8.2.7.1. Additional Hepatic Data Collection in Participants Who Have Abnormal Liver 
Tests During the Study
Addit ional hepatic safet y data collect ion (hepat ic safet y eCRF) shoul d be pe rformed for 
participants who meet one or more of the fo llowing condi tions:
●Elevation of serum  ALT to ≥5 times ULN on two or more consecut ive blood tests (if 
baseline ALT <1.5 times ULN)
○In parti cipants wi th baseline ALT ≥1.5 times ULN, the thresho ld isALT ≥3times 
baseline on 2 or more consecutive tests.
●Elevated TBL to ≥2 times ULN (if baseline TBL <1.5 times ULN) (except for cases of 
known Gilbert’s syndro me)
○In parti cipants wi th baseline TBL ≥1.5 times ULN, the thresho ld should be TBL ≥2 
times b aseline.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
58●Elevation of serum  ALP to ≥2 times ULN on two or more consecut ive blood tests (if 
baseline ALP <1.5 times ULN)
○In parti cipants wi th baseline ALP ≥1.5 times ULN, the thresho ld is ALP ≥2times 
baseline on two or more consecutive blood tests.
●Hepatic event considered to be a SAE
●Discont inuat ion of study  drug due to a hepat ic event (Section 7.1.2 )
Note that the interval between the two consecut ive blood tests shoul d be at l east 2 days.
8.2.8. Serious Infections and Opportunistic Infections
Com pletion of the Infect ion eCRF is required for each infect ion reported as an AE or SAE. The 
sponsor will ident ify infect ions considered to be opportunist ic based on the arti cle by Wint hrop 
et al. (2015) (Appendix 10.7).
8.3. Adverse Events and Serious Adverse Events
Adverse events will be reported by  the parti cipant (or, when appropri ate, by  a caregiver, 
surrogate, or the participant's legally authorized representative).
Adverse events in this study  will be categori zed based on thei r relatedness either to the study  
drug or vaccine products.
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study  procedures, or that 
caused the participant to discont inue the study  drug or the study  (see Section 7).
Product complaints are covered in Secti on8.3.7 .
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
Collection of AEs and SAEs
All SAEs will be co llected fro m thetime of the participant’ ssigning of the ICF until 
participat ion in study  has ended.
Likewise, a ll AEs will be collected from the from the signing of the study  ICF until participat ion 
in study  has ended.
Adverse events that begin before the start of study  intervent ion but after signing of the ICF will 
berecorded on the AEeCRF.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
59Reporting of AEs and SAEs
Although all AEs after signing the ICF are recorded by the site in the eCRF/electroni c data entry , 
SAE reporting to sponsor begins after the participant has signed the ICF and has received study 
drug. However, if an SAE occurs after signing the ICF, but prior to receiving lebrikizumab , it 
needs to be reported ONLY if it is con sidered reasonably possibly related to study  procedures.
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours, as indicated in Appendix 10.3. The invest igator will 
submit any  updated SAE data to the sponsor within 24 hours of i t being available.
Invest igators are not obligated to actively seek AE sor SAE safter concl usion of the study  
participat ion. However, if the invest igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study , and he/she considers the event to be reasonably  
related to the study  intervent ion or study  parti cipati on, the invest igator must prompt ly notify  the 
sponsor.
8.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the procedures 
for com pleting and transmitt ing SAE reports are provided in Appendix 10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal quest ioning of the participant is the preferred method to i nquire about AE
occurrences .
8.3.3. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/contacts. All SAEs and AE SIs (as defined in Sect ion 8.3.6 )will be followed 
until reso lution, stabilization, the event is otherwise explained, or the participant is lost to follow -
up (as defined in Sect ion7.3). Further information on fo llow-up procedures i s provi dedin 
Appendix 10.3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the saf ety of parti cipants and the safet y of a study  
intervent ion under clinical investigat ion are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  intervent ion und er clinical  investi gation. The 
sponsor will co mply wi th country -specific regulatory  requi rements relating to safet y reporti ng to 
the regulatory  authori ty, Inst itutional Review Boards (IRB)/Independent Ethics Committees 
(IEC) , and invest igators.
An invest igator who receives an invest igator safety report describing a SAE or other specific 
safet y informat ion (e.g., summary  or list ing of SAEs) from the sponsor will review and then file 
it along wi th the IBand will notify the IRB/IEC, if appropriate according t o local requi rements.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
608.3.5. Pregnancy
Pregnancy (maternal or paternal exposure to study  drug ) does not meet the definit ion of an AE.
However, to fulfill regulatory  requi rements, any pregnancy  should be reported following the 
SAE process described in Appendix 10.4 to collect data on the outcome for both mother and 
fetus.
Details o f all pregnancies in female participants and female partners of male participants will be 
collected after the start of study  intervent ion and for at least 18 weeks after the l ast dose.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of learning 
of the pregnancy  and shoul d follow the procedures outlined in Ap pendix 10.4.
Abnorm al pregnancy outcom es (e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopi c pregnancy ) are considered SAEs.
8.3.6. Adverse Events of Special Interest
Adverse events of special interest for this study  include:
conjunctivitis
herpes infect ion or zoster, and 
parasit ic infect ion or an infect ion related to an intracellular pathogen.
If these AESIs are reported, sites will be prompted to collect additional data.
8.3.7. Product Complaints
A product complaint is any written, electronic, or oral communicat ion that alleges a deficiency
related to the identit y, qualit y, durabilit y, reliabilit y, safety, effect iveness, or performance of a
Lilly product after it is released for distribut ion. When the abilit y to use the product safely is 
impacted, the fo llowing are also product complaints: 
a.Deficiencies in labeling informat ion, and
b.Use errors for device or combinat ion products due to ergonom ic design elements of the 
product.
Sponsor collects product complaints on investigational products and drug delivery systems used 
in clinical studies to ensure the safet y of study  participants, monitor qualit y, and facilitate 
process and product improvemen ts.
Com plaint s are al so collected on comparators and other materials supplied, as required and 
instructed for the study .
Parti cipants will be instructed to contact the invest igator as soon as possible if they have a 
complaint or probl em wi th the study  drug or drug delivery system, so that the situation can be 
assessed.
Product complaints will be reported by  the invest igator to the sponsor per instructions provided 
on the study  specific Product Complaint Form.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
618.4. Treatment of Overdose
In case of suspected over dose, hematology , chemistry , vital signs, and oxy gen saturati on shoul d 
be monitored and supportive care provided as necessary .
In the event of an overdose, the invest igator should:
1.Contact the medical monitor immediately .
2.Closely  monitor the parti cipant for any  AE/SAE and laboratory  abnorm alities unt il 
lebrikizumab can no l onger be detected sy stemically  (at least 18 weeks ).
Decisio ns regarding dose interruptions or modifications will be made by the invest igator in 
consultat ion with the medical monitor based on the clinical evaluation of the participant.
8.5. Pharmacokinetics
Study visits and times
At the visit s and t imes specified in the SoA (Section 1.3), venous blood samples will be co llected 
to determine the serum concentrati ons of  lebrikizumab . The actual  date and time (24- hour clock 
time) of dosing and sample co llection must be recorded accurately on the appropriate forms.
Collection, handling, and analysis of samples
Instructi ons for the collect ion and handling of bio logical samples will be provided by the 
sponsor. 
As stated in Appendix 10.2, samples will be analyzed at a laboratory  approved by  the sponsor. 
Concentrations of lebrikizumab will be assayed using a validated PK assay . Analyses of samples 
collected from participants who received placebo are not pl anned.
Additional and unused samples
Any excess samples collected for PK testing may be used for exploratory  analyses such as 
bioanalyt ical methods development, assay  validat ion or cross -validat ion exercises, protein 
binding, and/or metabo lism w ork.
In the case of systemic allergic/hypersensit ivity reacti ons, addi tional blood sam ples will  be 
obtained for PK analyses (Section 8.2.4 and Appendix 10.5).
Genet ic analyses will not be performed on these blood samples unless consent for t his was 
included in the informed consent. Participant confident iality will be m aintained. 
Unblinding
Drug concentration informat ion that mayunblind the study  will not be reported to invest igative 
sites or to personnel who are blinded to study  data .
Sample retention
The purpose of retention, the maximum duration of retent ion, and facilit y for long-term storage 
of samples is described in Appendix 10.1, Secti on 10.1.12 .During the sample retention t ime, PK 
samples remaining after the bioanalyses may be used for exploratory  analyses such as 
metabo lism work, protein binding, and /or bi oanalyti cal assay  validat ion or bi oanaly tical method 
cross -validation exercises.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
628.6. Pharmacodynamics
Pharmacodynamic parameters a re not evaluated in this study .
8.7. Genetics
A who le blood sample will be co llected for pharmacogenet ic analysis as specified in the SoA 
(Secti on 1.3), where local regulat ions allow.
Sample use
Samples will beused only  for investi gations rel ated to di sease and drug or class of drugs under 
study  in the context of this clinical program. They  will not be used for broad exploratory  
unspecified disease or populat ion genetic analysis. Genet ic variat ion may impact a participant’s 
response to study  intervent ion, suscept ibilit y to, and severit y and progressi on of  disease. 
Variable response to study  intervent ion may be due to genetic determinants that impact drug 
absorpti on, di stribut ion, metabo lism, and excret ion; mechanism of act ion of the drug; disease 
etiology; and/or m olecular subt ype of the disease being treated.
Samples will  be stored, and analysis may be performed on genet ic variants though t to pl ay a rol e 
in AD. In the event of an unexpected AE or the observat ionof unusual  response, the sam ples 
may be analyzed to evaluate a genet ic association with response to lebrikizumab . These 
investigat ions m ay be limited to a focused candidate gene study  or, if appropriate, genome- wide 
associ ation studi es may be perform ed to ident ify regions of the geno me associated with the 
variabilit y observed in drug response. 
Addit ional analyses m ay be conducted if it is hypothesized that this may  help further understand 
the clinical data.
Confidentiality
All samples will be coded with the participant number. These samples and any data generated 
can be linked back to the participant only by the investigative site personnel. The sponsor will 
store the blood and/or DNA samples in a secure storage space with adequate measures to protect 
confident iality.
Unblinding
Pharmacogenet ic informat ion that mayunblind the study  will not be reported to investigative 
sites or to personnel who are blinded to study  data .
Sample retention
The samples will be retained at a facilit y selected by the sponsor or its designee. The samples 
will be retained as long as research on the study  intervent ion or study  indicat ion continues, but 
no longer than the m aximum  retent ion time specified in Appendi x 10.1, Secti on 10.1.12 , or other 
period as per l ocal requi rements.
8.8. Biomar kers
Biomarkers will  not be assessed in this study.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
638.9. Immunogenicity Assessments
Visits and times
At the visit s and t imes specified in the SoA (Secti on 1.3), predose venous blood samples will be 
collected to determine the antibody  producti on against lebrikizumab . 
The actual  date and time (24- hour clock time) of each sample co llection will be recorded.
To aid interpretati on of  these results, a predose blood sample for PK analysis will be collected at 
the sam e time points.
Sample collection, handling, and use
Instructi ons for the collect ion and handling of blood samples will be provided by the spo nsor.
Immunogenicit y will be assessed by  a validated assay  designed to detect anti -drug antibodies 
(ADAs) in the presence o f lebrikizumab at a l aboratory  approved by  the sponsor , as indicated in 
Appendix 10.2.Antibodies may be further characterized for their abilit y to neutralize the activit y 
of lebrikizumab .
Unblinding
Immunogenicit y test inform ation that mayunblind the study  will not be reported to invest igative 
sites or to personnel who are blinded to study  data .
Sample retention
The purpose of retention, the maximum duration of retent ion, and facilit y for long-term storage 
of samples is described in Append ix 10.1, Secti on10.1.12 .
8.10. Medical Resource Utilization and Health Economics
Not applicable to this study .
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
649. Statistical Considerations
9.1. Statistical Hypotheses
Study  KGAK is a descript ive study  with no planned hy pothesis testing. Confidence intervals 
(CIs) will be used to compare seroresponses for lebrikizumab -and placebo -treated participants.
9.2. Sample Size Determination
Approximately 240participants will be rando mlyassigned to study  interventi on (1:1 rati o for 
lebrikizumab:placebo) such that approximately 218evaluable per protocol  (PP) participants 
complete the study .
The sample size for this study  was determined based on the fo llowing informat ion:
The percentage of study  participant s with posi tive response to the tetanus vaccinat ion at 
Week 16 is83.7% and 83.3% for active treatment and placebo, respectively (Blauvelt et 
al. 2019 ). 
The percentage of study  participant s with human com plement serum  bacteri cidal assay
(hSBA )-Meningococc alCtotal seroresponse at Day  29 is90% ( Tipton et al. 2019 , 
adjusted for adul t popul ation)
.
Assuming the observed booster response to tetanus toxoid for both l ebrikizumab and placebo is 
83% at Week 16, with 109 participants per arm, the Wald 2-sided 90% CI for the difference in 
booster response is(-0.08, 0.08) .
Similarly ,assuming the positive ant ibody  response to MCV for both lebrikizumab and placebo is 
90% at Week 16, with 109 participants per arm, the Wald 2-sided 90% CIfor the difference in 
booster response is (-0.07, 0.0 7).
9.3. Populations for Analyses
The fo llowing participant populat ions are defined:
Population Description
Intent -to-Treat (ITT) All participants assigned to study drug , regardl ess of  whether they  
take any  doses of study  drug, or if they took the correct study drug .
Parti cipants will be analyzed according to the treatment group to 
which they  were rando mly assigned.
Per Protocol (PP) All participants in the safety  popul ation who complete the 
Week 16 (Visit 10) evaluation wit hout any  significant protocol 
violations.
Safety All p articipants randomly  assigned to study  drug and who take at 
least 1 dose of study  drug. Parti cipants will be analyzed according 
to the study  drug they actually  received .
Pharmacokinet ic Analysis All rando mized participants who received at least 1 full dose of 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
65study  drug and at least 1 postbaseline evaluable PK sample.
Immunogenicit yAnalysis A participant is evaluable for t reatment -emergent ADA if there is 
at least 1 non- missing test result for ADA for both the baseline and 
the postbaseline visits.
Abbreviations: ADA = anti -drug antibody; PK = pharmacokinetic.
The PP populat ion will include participants in the safet y popul ation without si gnificant protocol  
deviat ions(i.e., any  parti cipant or invest igator activit y that coul d have possibly  interfered wi th 
the therapeutic administration of the study  drug or the precise evaluat ion of the study  drug
efficacy). Significant protocol  deviat ionsinclude the fo llowing:
Used prohibited treatm entthat requi redperm anent discont inuat ion of the study  drug (see 
Secti on 7.1.2 ) 
Missed eit her one or both Week 12 or Week 16 study  visits (V isits 8 and 10)
Have not been compliant with the dosing regimen (i.e., participant s must receive 80% of  
the expected inject ions of study  drug and both of the vaccines during participat ion in the 
study )
Exceeded the out -of-the-visit window at the Week 16 vi sit (Vi sit 10) by  more than ± 7
days
Addit ional significant protocol deviat ionsmay be specified in the Statist ical Analysis Plan (SAP) 
prior to unblinding. 
9.4. Statistical Analyses
9.4.1. General Considerations
Statistical analysis o f this study  will be the responsibilit y of the sponsor or its designee. All 
statist ical processing will be performed using SAS®unless otherwise stated. The primary  
analysis of the co-primary endpo ints will be performed for the PPparticipant populat ion when all 
participants have completed Week 16.Analysis of the co-primary, secondary, and exploratory 
endpo ints will be performed for the ITT participant populat ion.
Descript ive statistics will be provi ded for all  efficacy  and safet y endpo ints. For categori cal 
endpo ints, the number and percentage of participants in each category will be presented. For 
continuous endpo ints, descri ptive stati stics will include the following:
the number of participants
mean
standard deviat ion (SD)
median
minimum ,and 
maximum. 
Parti cipants’ baseline characterist ics related to efficacy analyses will be provi ded with 
descript ive statistics for each treatm ent group.
The Pruritus NRS weekly mean will be calculated as fo llows: 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
66The m ean of  each participant ’s baseline and post- baselin e Pruri tusNRS scores will be 
computed for each week based on the previous 7 days. 
The weekly  mean will  be calculated if a participant has responses for Pruritus NRS on at 
least 4 of the 7 day s of the week. 
If the participant has 3 or fewer Pruritus NRS responses, the mean value for that item will be 
considered missing. All Pruritus NRS efficacy endpoint analyses will be conducted on the 
weekly mean. 
The Sl eep-Loss weekly mean will be calculated similar to the Pruritus NRS weekly mean. All 
Sleep-Loss eff icacy  endpoint analyses will be conducted on the weekly mean.
The number of participants in each analysis set will be summarized. Reasons for study  drug 
discontinuat ionand for study  discontinuation during the treatm ent peri odwill be summarized 
using freq uencies and percentages by  treatm ent group.
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a princi pal feature of the protocol. Any other change to the data analysis 
methods described in the p rotocol , and the j ustification for making the change, will be described 
in the SAP and the clinical study  report.
Addit ional exploratory  analyses of the data maybe conducted as deemed appropriate. The SAP
will be finalized prior to unblinding. It will include a more technical and detailed descript ion of 
the stati stical analyses described in this sect ion.
9.4.1.1. Participant Disposition
A detailed description o f participant disposi tion will be provided, including a summary o f the 
number and percentage of participants entered into the study  and rando mized, and number and 
percentage of participants who complete or discontinue the study  or the study  drug , both overall 
and by  reason for di scont inuat ion. A summary  of important and significant protocol deviat ions 
will be provided.
9.4.1.2. Participant Characteristics
Dem ographic data are collected and summarized to dem onstrate that the study  popul ation 
represents the target participant populat ion. A summary  of demographic data, baseline 
participant characterist ics, historical diagnoses, preexist ing condit ions, and prior therapies will 
be summarized by treatm ent group using descriptive statist ics. Other participant characterist ics 
will be summarized by  treatm ent group as deemed appro priate.
9.4.1.3. Concomitant Therapy
Previous and concomitant medicat ions will be summarized by treatment group and will be 
presented by anatomical therapeut ic chemical (ATC) drug classes using the latest versio n of the 
World Heal th Organizat ion (WHO) drug dict ionary. 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
679.4.1.4. Exposure and Compliance
The extent of exposure to study  drug in each treatment group will be summarized by total 
number of days of exposure, total number of injectio ns, number of missed inject ions, and 
number and percentage of participant s who are compliant. 
The total number of vaccines of each t ype in each treatment group will be summarized by the 
total number of vaccines .
A participant will be considered compliant with the dosing regimen if the participant received 
100% of the expected number of study  drug inject ions and vaccines while enrolled in the study.
9.4.2. Co-Primary Analys es 
The co-primary endpo ints, as described in Sect ion 3,will be analyzed for the PPparticipant
popul ationto com pare the percentage sof lebrikizumab -treated andplacebo -treated participants
using the methods for categorical endpo ints described in Section 9.4.1 .In addition, a 90% CIfor 
the difference between treatment groups will be constructed using the stratified Newco mbe 
approach (Yan and Su 2010; Kim and Won 2013)
. Missing values will not be imputed.
9.4.3. Secondary Analyses
Descript ive statistics, as described in Section 9.4.1 , will be provided for the ITT parti cipant 
popul ationfor the efficacy  and quali ty-of-life measures described in Section 3.
For the anti -tetanus toxoi d IgG ant ibody  concentrati on and Meningococcal  Group C serum  
bacteri cidal ant ibodies , the pre -and post -vaccinat ion geom etric mean t iters will be analyzed .
9.4.3.1. Missing Data
The m ethod of handling missing efficacy data will be as fo llows for endpoints:
Percentage of participants at Week 16 achieving :
an IGA score of 0 or 1 and a reduction of ≥2 points from baseline
≥75% reduction fro m baseline in EASI score (EASI -75)
≥90% reduction fro m baseline in EASI score (EASI -90)
≥4-point improvement fro m baseline in Pruritus NRS score in participants with baseline 
score of ≥4
For participants who receive systemic rescue treatment or wi thdraw from  the study  due to l ack of 
efficacy , values should be set to the participant ’s baseline value subsequent to this t ime through 
Week 16. The Markov Chain Monte Carlo (MCMC )mu
ltiple imputation will be used to handle 
the rem aining missing data. Im putati on will be conducted within each treatm ent group 
independent ly so the pattern of missing observat ions in one treatment group cannot influence the 
missing value imputation in the other treatm ent group. For each imputation process, 25 datasets 
with imputati ons will  be calculated. Each complete data set will be analyzed with the specified 
analysis. The results from these analyses will be combined into a single inference using SAS 
PROC MIANALYZE.
For binary  responses rel ated to EASI and IGA, the b inary  response variables will be calculated 
based on the mult iply imputed datasets that have been created. Because the MCMC algorithm is 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
68based on the mult ivariate normal model, imputed values for IGA will not generally be one of the 
discrete val ues used in IGA scoring (0, 1, 2, 3, or 4). Therefore, to derive the binary  IGA 
response variable, standard rounding rules will be applied to the imputed values. For example, if 
a participant has an IGA score imputed as 1.4 (and assuming a baseline IGA score of 3), t he 
imputed value would be rounded down to 1, and the minimum change fro m baseline of 2 would 
have been met. This participant would be considered a responder. For derivat ion of an EASI -75 
and EASI -90 responses, no rounding will be performed. 
The imputed We ek 16 EASI value will be compared directly to the observed baseline EASI 
value to determine whether a reduction of at least 75% was achieved for EASI -75. The imputed 
Week 16 EASI value will be co mpared direct ly to the observed baseline EASI value to 
determ ine whether a reduction of at least 90% was achieved for EASI -
90.Imputati on of  
continuous data will be analogous to that of binary vari ables ; details will be provided in the SAP .
A total o f 2 random seeds will be needed to impute IGA for the 2treatm ent g roups. The 2seeds 
have been pr e-specified by a rando m-
number generator:
IGA: Lebrikizumab 250 mg Q2W: Seed = 970309630
IGA: Pl acebo Q2W: Seed = 1477266806
A total o f 2 random seeds will be needed to impute Pruritus NRS for the 2 treatm ent groups. The 
2seeds have been prespecified by  a random -number generator:
NRS: Lebrikizumab 250 mg Q2W: Seed = 1611917356
NRS: Placebo Q2W: Seed = 1087836192
A total o f 2 random seeds will be needed to impute EASI for the 2 treatm ent groups. Those 2 
rando m seeds have been prespecified by using a rando m-number generator:
EASI: Lebrikizumab 250 mg Q2W: Seed = 353985587
EASI: Placebo Q2W: Seed = 1828572477 
9.4.4. Exploratory Analyses
Exploratory  analyses will be described in detail in the SAP that is finalized prior to unblinding .
9.4.5. Safety Analyse s
All AEs occurring during the study  will be recorded and coded using the MedDRA dict ionary. 
Treatment -emergent AEs (TEAEs) are defined as AEs with an onset date on or after the date of 
the first inject ion of study drug. TEAEs will be summarized by treatment group, including the 
number of participant s reporti ng an event, system organ class, preferred term, severit y, 
relationship to study  drug, and seri ousness for the safet y popul ation. All SAEs as well as AEs 
that led to study  discont inuat ion will be listed by participant .
9.4.6. Pharmacokinetic Analyses
Lebri kizumab PK data will be summarized using descript ive statistics. 
Data from this study  maybe combined wit h data from other studies to better characterize the PK 
of lebrikizumab, as well as to explore the relat ionship between exposure and efficacy and/or 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
69safet y outcom es. In this case, a separate PK analysis plan will be developed, and the resul ts of 
these analyses will be described in a separate PK report .
9.4.7. Immunogenicity Data Analysis 
The ADA variables will be analyzed using descriptive statist ics. Drug concentration data will be 
examined and the influence of ADAs on individual concentration- time profiles will be evaluated. 
Assessment of impact of ADA on safet y and efficacy  may be provi ded.
Listings and appropriate summary statist ics will be provided for immunogenicit y data. The 
frequency  and percentage of participants with preexist ing ADA and with treatm ent-emergent 
ADAs (TE-ADAs) to lebrikizumab may be tabulated.
Parti cipants wi th TE-ADA are defined as those with a titer 2 -fold (1 dilut ion) greater than the 
minimum required dilut ion if no ADAs were detected at baseline (treatment -induced ADA) or 
those wi th a 4-fold (2 dilutions) increase in titer compared to baseline if ADAs were detected at 
baseline (treatment -boosted ADA). 
The frequency of neutralizing ant ibodies may also be tabulated in partici pants wi th TE-ADA .
The rel ationship between th e presence of ant ibodies and the PK parameters and drug response 
(including safet y and efficacy )to lebrikizumab may be assessed.
9.4.8. Other Analyse s
Subgroup analyses will be conducted for the co-primary endpo ints for the ITT participant
popul ation.Subgroups for the ITT participant populat ionto be evaluated may  include age, sex, 
race, and other as deemed appropriate.
Definit ions of the subgroups and any subgroup -specific analyses will be provi dedin the SAP.
All subgroup analyses will be considered explorator y.
9.5. Interim Analyses 
No interim statistical analyses prior to participants’ complet ing the Week 16 visit are pl anned for 
this study .
Adatabase l ock and unblinding will occur, and the primary analysis will  be perform ed at the 
time (that is, a cut -off date) the last participant completes Week 16 or the ETvisit ofStudy  
KGAK . This database lock will include all data collected by  the cut -off date.
Thefinal database lock and analyses will then b e conducted after all the participants have 
completed the follow -up peri od of  Study  KGAK .
Depending on the regulatory  submissi on timeline, the primary and final database locks may be 
combined ;that is, one final database lock will occur after all the parti cipants have either 
completed the follow -up peri od of  Study  KGAK , or di scontinued the study early or entered the 
long-term extensio n study (DRM06 -AD07 /J2T-DM-KGAA ).
Unblinding details are specified in the Unblinding Plan sect ion of the SAP or in a separate
unblinding plan document.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
709.6. Data Monitoring Committee (DMC)
The DSMB used acro ss the lebrikizumab program  will be used in this study . ADSMB is a ty pe 
of DMC.
For details on the DSMB , refer to Appendix 10.1, Secti on10.1.5 .
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
7110. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declarat ion of Helsinki and Council for International Organizat ions of Medical Sciences 
(CIOMS) International Ethical Guidelines
Applicable Internat ional Council for Harmonisation (ICH) Good Clinical Practice (GCP) 
Guidelines
Applicable laws and regulations
The pr otocol , protocol  amendments, ICF, I B, and other relevant documents (e .g., adverti sements) 
must be submitted to an IRB/IEC by  the invest igator and reviewed and approved by the IRB/IEC
before the study  is init iated.
Any amendments to the protocol will requir e IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to study  parti cipants.
The invest igator will be responsible for the fo llowing:
Provi ding wri tten summaries of the st atus of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC
Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required by 
IRB/IEC procedures
Provi ding oversight of study  conduct for parti cipants under thei r responsibilit y and 
adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulat ion 
536/2014 for clinical studies (if applicable), and all other applicable local regulat ions
Invest igator sites are compensated for participat ion in the study as detailed in the clinical trial
agreem ent.
10.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient , accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties. Investi gators are 
responsible for providing informat ion on financ ial interests during the course of the study  and for 
1 year after complet ion of the study .
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
7210.1.3. Informed Consent Process
The invest igator or his/her representative will explain the nature of the study , including the risks 
and benefits, to the parti cipant or his /her legally  authori zed representati ve and answer all
questions regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants or thei r legally  
authori zed representative will be required to sign a statement of inform ed consent that meets the 
requi rements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portabilit y and 
Accountabilit y Act (HIPAA) requirements, where applicable, and the I RB/IEC or study center.
The m edical  record m ust include a statem entthat wri tten inform ed consent was obtained before 
the participant was enter ed in the study  and the date the written consent was obtained. The 
authori zed person obtaining the informed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF(s) during th eir 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  authori zed 
representati veand is kept on file.
Parti cipants who are rescreened are required t o sign a new ICF and will be assigned a new 
participant number .
10.1.4. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant records ,datasets
or tissue samples that are transferred to the sponsor will contain the identifier only; participant 
names or any  information which would make the participant ident ifiable will not be transferred.
The parti cipant must be inform ed that hi s/her personal  study -related data wil l be used by  the 
sponsor in accordance wit h local data protecti on law. The l evel of disclosure m ust also b e 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent .
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by Clinical 
Qualit y Assurance auditors or other authorized personnel appo inted by  the sponsor, by  
appropriate IRB/IEC members, and by inspectors from regulatory  authori ties.
The sponsor has proce sses in place to ensure data protection, informat ion securit y and data 
integrity.These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data securit y breach.
10.1.5. Committee Structure
As stated in Sect ion 9.6, the DSMB used in this study  is the same DSMB used across the 
lebrikizumab program.
This independent DSMB is comprised of m embers who are independent of the st udy sponsor and 
study  invest igators . This committee will monitor participant safet y by conduct ing formal reviews 
of accumulated safet y data that is blinded by  treatment group . If requested, the DSMB may have 
access to the treatment allo cation code or any  other requested data for the purposes of a risk -
benefit assessment.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
73The DSMB will provide the sponsor with appropriate recommendat ions on the conduct of the 
clinical study  to ensure the protection and safet y of the participants enrolled in the study. The 
DSMB will also inst itute any  measures that m ay be requi red for ensuring the integrit y of the 
study  resul ts during the study  execut ion.
All activities and responsibilit ies of the DSMB are described in the Lilly DSMB charter.
10.1.6. Dissemination of Clinical Study Da ta
Reports
The sponsor will disclose a summary o f study  information, including tabular study results, on 
publicly  available websites where required by  local law or regul ation.
Data 
The sponsor provides access to all individual part icipant data collected during the trial, after 
anonymizat ion, wi th the excepti on of  PK or genetic data. Data are available to request 6 months 
after the indicat ion studied has been approved in the US and EU and after primary publication 
acceptance, whichever is later. No expirat ion date of data requests is current ly set once data are 
made available.
Access i s provi ded af ter a proposal  has been approved by  an independent review committee 
ident ified for this purpose and after receipt of a signed data sharing agreement. Data and 
docum ents, including the study  protocol , SAP , clinical study  report, bl ank or annotated CRFs, 
will be provided in a secure data sharing environment for up to 2 y ears per proposal.
For details on submitting a request, see the instructio ns provided at www.vivli.org.
10.1.7. Data Quality Assurance
All participant data relat ing to the study  will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (e .g., laboratory  data). The invest igator is 
responsible for verifyi ng that data entri es are accurate and correct by  physically  or electronically 
signing the eCRF.
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF. Source data might include laboratory  tests, medical records, 
and clinical notes .
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  
agency  inspect ions and provide direct a ccess to source data documents.
Moni toring details describing strategy  (e.g., risk -based init iatives in operations and qualit y such 
as Risk Management and Mit igation Strategies and Analyt ical Risk-Based Monitoring), methods, 
responsibilit ies and requirements, including handling of nonco mpliance issues and monitoring 
techniques are provid ed in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  includin g qualit y 
checking o f the data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals (e
.g., Contract 
Research Organizat ions).
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
74Study  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF by  authori zed si te personnel  are accurate, com plete, and verifiable fro m source 
docum ents; that the safet y and ri ghts of  parti cipants are being pr otected; and that the study  is 
being conducted in accordance with the current ly approved protocol and any other study 
agreem ents, ICH GCP, and all applicable regu latory requirements.
Records and documents, including signed ICFs, pertaining to the conduct o f this study  must be 
retained by the invest igator for the time period outlined in the Clinical Trial Agreement (CTA) 
unless local regulat ions or inst itutional policies requi re a l onger retenti on peri od. No records m ay 
be destroy ed during the retention peri od wi thout the wri tten approval  of the sponsor. No records 
may be transferred to another location or party  without wri tten notificat ion to the sponsor .
In addit ion, sponsor or its representatives will periodically check a sample of the participant data 
recorded against source documents at the study  site.The study  may be audi ted by sponsor or its 
representatives, and/or regulatory  agencies at any  time. Invest igators will be given noti ce before 
an audit occurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture sy stem  (EDC) will be used in this study  for the collect ion of eCRF 
data. The invest igator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system. The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the eCRF .
Addit ionally , electroni c Clinical Outcome Assessment (eCOA) data ( participant -focused 
outcom e instrument ) will be direct ly recorded by  the participant (electronic patient diary and 
electroni c tablet on si te)or invest igator site personnel (electroni c tablet on si te).The eCOA data 
will serve as the source documentation and the investigator does not maintain a separate, written 
or electroni c record of these data.   
Data collected via the sponsor- provided data capture system (s)will be stored at third- party  sites. 
The invest igator will have cont inuous access to the data during the study and unt il 
decommissio ning of the data capture sy stem (s).Prior to decommissio ning, the invest igator will 
receive an archival copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory test data, will be stored electronically  in 
the central  vendor’s database system and electronic transfers will be provi ded to the invest igator 
for review and retent ion.Data will subsequent ly be transferred fro m the central  vendor to th e 
sponsor data warehouse.
Data from co mplaint forms submitted to sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the invest igator’s site.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
75Data reported on the CRF or entered in the eCRF that are transcribed fro m source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on the 
study . Also, current m edical records must be available.
Definit ion of what constitutes source data can be found in Section 10.1.7 .
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  is open for recruit ment of participants.
The study  or a study site will be discont inued if the sponsor or its designee judges it necessary  
for medical, safet y, regul atory , or other reasons consistent with applicable laws, regulat ions, and 
GCP . Study  sites will  be closed upon study  com pletion. A study  site is consi dered cl osed when 
all requ ired docum ents and study  supplies have been collected and a study -site closure visi t has 
been performed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the inten ded terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
●Failure of the invest igator to comply wit h the protocol, the requirements of the 
IRB/IEC or local healt h authorit ies, the sp onsor ’s procedures, or GCP guidelines
●Inadequate recruit ment of parti cipants by  the investi gator
●Discontinuati on of  further study  drug development
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by the applicable 
regul atory  requi rements. The investigator shall prompt ly inform the participant and assure s
appropriate participant therapy  and/or foll ow-up.
10.1.10. Publication Policy
In accordance with the sponsor’s publication po licy the results of this study will be submitted for 
publicat ion by a peer -reviewed journal.
10.1.11. Investigator Information
Physicians with a specialt y in dermatol ogywill participate as invest igators in this clinical trial.
Physicians and other qualified healt hcare professio nals wit h other specialt ies and experience in 
treatm ent of patients with AD may  also parti cipate as invest igators.
10.1.12. Long -Term S ample Retention
Sample retenti on enables use of new techno logies, response to regul atory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of
lebrikizumab or after lebrikizumab beco me(s) commercially available.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
76Sample Type Custodian Retention Period After Last 
Participant Visita
PK Sponsor or Designee Up to 1 year
Pharmacog enetics Sponsor or Designee Up to 7years
Immunogenicity Sponsor or Designee Up to 15years
aRetention periods may differ locally .
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
7710.2. Appendix 2: Clinical Laboratory Tests
The tests detailed in the table below will be performed by the central laboratory orby the local 
laboratory , as specified in the table .
Protocol -specific requirements for inclusio n or exclusio n of participants are detailed in Sect ion 5
of the protocol.
Addit ional tests may be performed at any  time during the study as determined necessary  by the 
investigator or required by  local regulati ons.
Pregnancy testing is described in the SoA and in the table below.
Invest igators must document their review of each laboratory  safety  report.
Laboratory testresul ts that coul d unblind the study will not be reported to invest igative sites or 
other blinded personnel.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
78Clinical Laboratory Tests Comments
Hematology Assay ed by Lilly -designated laboratory .
Hemoglobin
Hematocrit
Erythrocy te count (RBCs -RedBlood Cells)
Mean cell volume 
Mean cell hemoglobin
Mean cell hemoglobin concentration 
Leukocytes (WBCs -White Blood Cells) 
Differential
Neutrophils, segmented
Lymphocy tes
Monocytes
Eosinophils
Basophils
Platelets
Cell morphology (RBCs and WBCs)
Clinical Chemistry Assay ed by Lilly -designated laboratory .
Sodium
Potassium
Chloride
Bicarbonate
Total bilirubin
Direct bilirubin
Indirect bilirubin
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT)
Blood urea nitrogen (BUN)
Creatinine 
Uric acid
Total protein
Albumin
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
79Clinical Laboratory Tests Comments
Calcium
Phospho rus
Glucose
Total c holesterol 
Lactic dehydrogenase (LDH)
Urinalysis Assay ed by Lilly -designated laboratory .
Specific gravity
pH
Protein
Glucose
Ketones
Bilirubin
Urobilinogen
Blood
Nitrite
Urine leukocyte esterase
Hormones (female)
Serum Pregnancy Assay ed by Lilly -designated laboratory.
Urine Pregnancy Evaluated locally .
Serology Assay ed by Lilly -designated laboratory .
HIV testing Assay ed by Lilly -designated laboratory .
Hepatitis C Virus (HCV) testing: Assay ed by Lilly -designated laboratory. 
HCV antibody 
HCV RNA
Hepatitis B Virus (HBV) testing: Assay ed by Lilly -designated laboratory.
HBV DNA
Hepatitis B core antibody (Anti -HBc) 
Hepatitis B surface antigen (HBsAg) 
Hepatitis B surface antibody (anti -HBs)
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
80Clinical Laboratory Tests Comments
Immunoglobulins Assay ed by Lilly -designated laboratory. 
Total immunoglobulin G (IgG)
Total immunoglobulin A (IgA)
Vaccine Seroresponse Assay ed by Lilly -designated laboratory. Results will 
not be provided to the investigative sites.
Anti-tetanus toxoid IgG antibody
Meningococc alGroup C serum bactericidal antibodies 
(human complement serum bactericidal assay [hSBA ])
Pharmacokinetic Samples :lebrikizumab
concentrationAssay ed by Lilly -designated laboratory. Results will 
not be provided to the investiga tive sites.
Pharmacogenetic sample Assay ed by Lilly -designated laboratory. Results will 
not be provided to the investigative sites.
Immunogenicity (ADA) Samples Assay ed by Lilly -designated laboratory. Results will 
not be provided to the investigative sites.
Anti-lebrikizumab antibodies 
Anti-lebrikizumab neutralizing antibodies
ADA = antidrug antibody.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
8110.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a patient or clinical study  parti cipant, tem porally 
associ ated wi th the use of study  intervent ion, whether or not considered related to the study  
intervent ion.
NOTE: An AE can therefore be any unfavor able and unintended sign (including an abnormal 
laboratory  finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of study  intervent ion.
Events Meeting the AE D efinition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments (e .g., ECG, radio logical scans, vital signs measurements), 
including those that worsen fro m baseline, considered clinically significant in the medical 
and scient ific judgment of the invest igato r (i.e., not related to progression of underlying 
disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study  inter
vention administration even 
though it m ay have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose should be reported regardless of sequelae.
Events NOT Meeting the AE D efinition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condit ion.
The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
Medical or surgical procedure (e .g., endoscopy ,appendectomy): the condit ion that l eads 
to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospital).
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
82Anticipated day -to-day fluctuations of pre -exist ing disease(s) or con dition(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definit ion above, then it cannot be an SAE even if serious condit ions 
are met (e .g., hospitalizat ion for signs/symptoms of the disea se under study , death due to 
progression of disease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term  “life-threatening” in the definit ion of “serious”refers to an event in which the 
participant was at ri sk of death at the time o f the event. It does not refer to an event, which 
hypotheti cally  might have caused death, if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal for 
observat ion and/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Complicat ions that occur during hospitalizat ion are AEs. If a 
complicat ion prol ongs hospi talizati on or f ulfills any  other seri ous cri teria, the event i s 
serious. When in doubt as to whether “hospitalizat ion” occurred or was necessary, the AE 
shoul d be considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen fro m 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct norm al 
life funct ions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, and 
accidental  traum a (e.g., sprained ankle) which may interfere with or prevent everyday life 
funct ions but do not constitute a substant ial disruptio n.
e.Is a congenital anoma ly/birth defect
Abnorm al pregnancy outcom es (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) are considered SAEs.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
83f.Other situations:
Medical or scient ific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may  not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize t he 
participant or m ay requi re medical or surgi cal intervent ion to prevent one of the other 
outcom es listed in the above definit ion. These events should usually be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatm ent in an 
emergency room  or at hom e for allergic bronchospasm, blood dy scrasias or convulsio ns 
that do not result in hospitalizat ion, or development of drug dependency or drug abuse.
10.3.3. Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (e .g., hospital progress notes, laboratory  reports, and di agnosti cs reports) 
related to the event.
The invest igator will then record all relevant AE informat ionin the eCRF and the SAE 
inform ation, on a paper form .
It is notacceptable for the invest igator to send photocopies of the participant’s medical 
records to sponsor or designee in lieu of co mpletion of the AE eCRF page and SAE paper 
form.
There m ay be instances when copies of medical records for certain cases are requested by  
sponsor or desi gnee . In thi s case, all participant ident ifiers, wi th the except ion of the 
participant number, will be redacted on the copies of the medical records bef ore 
submissio n to sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during the 
study  and assi gn it to 1 of the following categories:
Mild: An event that is easily tolerated by the participant, causing minimal disco mfort and 
not interfering wit h every day act ivities.
Moderate: An event that causes sufficient disco mfort and interferes with normal 
everyday act ivities.
Severe: An event that preve nts normal everyday activit ies. An AE that is assessed as 
severe should not be confused with a SAE. Severe is a category  utilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when i t meets at l east 1 of the predefined outcomes as 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
84described in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE.
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relat ionship cannot be rul ed out.
The invest igator will use clinical judgment to determine th e relationship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration will be considered and invest igated.
The invest igator wil l also consul t the IB and/or Product Information, for marketed 
products, in his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be situat ions in which an SAE has occurred and the invest igator has minimal 
inform ation to include in the init ial report to sponsor or designee . However, i t is very  
important that the invest igator always make an assessment of causalit y for every  event 
before the ini tial transmissi on of the SAE data to sponsor or designee .
The invest igator may change his/her opinio n of causalit y in light of fo llow-up 
inform ation and send a SAE follow -up report wi th the updated causalit y assessment.
The causalit y assessment is one of the criteria used when determining regulatory 
reporting requirements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by sponsor or 
designee to elucidate the nature and/or causalit y of the AE or SAE as fully as possible . 
This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
If a participant dies during participation in the study or during a recognized fo llow-up 
period,the inv estigator will provide sponsor or designee with a copy  of any post -mortem 
findi ngs including histopathology .
New or updated informat ion will be recorded in the originally co mpleted eCRF.
The invest igator will submit any updated SAE data to sponsor or desig neewithin 
24hours of receipt of the information.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
8510.3.4. Reporting of SAEs
SAE Reporting via Paper CRF
The primary  mechanism  for reporting anSAE will be a study -specific paper SAE form 
thatwill be provided to the site.
The paper SAE forms will be transmitted to the sponsor by  a sponsor -designated 
method(s). 
Site staff m ust alert Lilly  Global Pat ient Safet y, or its designee, of any  SAE wi thin 
24hours of invest igator awareness of the event via a sponsor -approved method .
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE formwithin the designated reporting time frames.
Contacts for SAE reporting can be found on the SAE form .
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
8610.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
10.4.1. Definitions
Woman of Childbearing Potential (WOCBP)
A WOCBP i s defined a postmenarcheal female, who has not reached a postmenopausal state 
(12 continuous months of amenorrhea with no ident ified cause other than men opause), and has 
not undergone surgical sterilizat ion (removal o f ovari es and/or uterus).
Women NOT of Childbearing Potential (no n-WOCBP)
Women in the fo llowing categori es are not considered WOCBP
1.Prem enarchal
2.Prem enopausal  female wi th 1 of the f ollowing:
Docum ented hysterectomy
Docum ented bilateral  salpingectomy
Docum ented bilateral  oophorectomy
For individuals wit h perm anent infert ility due to an alternate medical cause other than the 
above, (e .
g., mullerian agenesis, androgen insensit ivity), invest igator discret ion shoul d be 
applied to determining study  entry .
NOTE : Documentation can come from the site personnel’s :review of the participant’s 
medical records, medical examinat ion, or m edical history  interview .
3.Postmenopausal  female is defined as, women with:
12 m onths of amenorrhea for women >55, with no need for follicle st imulat ing 
horm one ( FSH)
12 m onths of amenorrhea for women >40 y ears old wi th FSH ≥40 m IU/mL and no 
other m edical  condi tion such as anorexi a nervosa and not taking medications during 
the am enorrhea (e.g. oral contraceptives, hormones, gonadotropin releasing hormone, 
anti
-estrogens, sel ective estrogen receptor modulators [SERMs ], or chemotherapy  
that induced amenorrhea )
10.4.2. Contraception Guidance
See inclusio n criterion [9] (Secti on 5.1) for requi rements for female and male contraception.
10.4.3. Collection of Pregnancy Information
Male participants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant’s female 
partner who becomes pregnant while the male participant is in this study . 
After obtaining the necessary  signed informed consent from the pregn ant female partner direct ly, 
the invest igator will record pregnancy informat ion on the appropriate form and submit it to the 
sponsor within 24 hours of learning of the partner’s pregnancy. The female partner will also be 
followed to determine the outcome o f the pregnancy . Information on the status of the mother and 
child will be forwarded to the sponsor. Generally, the fo llow-up will be no l onger than 6 to 8
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
87weeks fo llowing the estimated delivery  date. Any  terminat ion of the pregnancy will be reported 
inclu ding fetal status (presence or absence of ano malies) andindication for the procedure. 
Female participants who become pregnant
The invest igator will co llect pregnancy information on any female participant who becomes 
pregnant while part icipating in this s tudy.The init ial informat ion will be recorded on the 
appropriate form and submitted to the sponsor within 24hours of learning o f a participant's 
pregnancy. 
The parti cipant will be fo llowed to determine the outcome of the pregnancy . The invest igator 
willcollect fo llow-up inform ation on the participant and the neonate and the informat ion will be 
forwarded to the sponsor. Generally, fo llow-up will not be required for longer than 6 to 8 weeks 
beyo nd the est imated delivery date. Any terminat ion of pregnancy will be reported, including 
fetal status (presence or absence of ano malies) or indicat ion for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  com plicat ion or 
elective termination o f a pregnancy  for medical  reasons will be reported as an AE or SAE. 
A spontaneous abortion (occurring at <2 0 weeks gestational age) or still birth (occurring at >20 
weeks gestational age) is always considered to be an SAE and will be reported as such. 
Any post -study pregnancy related SAE considered reasonably related to the study intervention 
by the investigator will be reported to the sponsor as described in Sect ion8.3.4 . While the 
investigator i s not obligated to actively  seek this inform ation in former study  parti cipants, he or 
she m ay learn of an SAE through spontaneous reporting.
Any female part icipant who becomes pregnant while participat ing in the study  will discont inue 
study  drug and be wit hdrawn fro m the study .
C O N FI D E N TI A L Pr ot o c ol  J 2 T -M C -K G A K /D R M 0 6 -A D 1 8 
8 8 1 0. 5. A p p e n di x 5: R e c o m m e n d e d L a b o r at o r y T e sti n g f o r S y st e mi c 
H y p e r s e n siti vit y E v e nt s 
L a b or at or y  t e sti n g s h o ul d b e p erf or m e d at t h e ti m e of a s y st e mi c h y p er s e n sit i vit y e v e nt. 
I m p ort a nt i nf or m at i o n a b o ut w h y , w h e n, a n d w h at t o t e st f or i s pr o vi d e d b el o w. T h e 
m a n a g e m e nt of t h e A E m a y  w arr a nt l a b or at or y  t e sti n g b e y o n d t h at d e s cri b e d b el o w a n d s h o ul d 
b e p erf or m e d a s cli ni c all y  i n di c at e d. 
L a b or at or y  t e sti n g d uri n g a s y st e mi c h y p er s e n sit i vit y  e v e nt i s n ot p erf or m e d f or di a g n o sti c 
p ur p o s e s. It s i nt e nt i s s e v er al f o l d: 
 T o h el p c h ar a ct eri z e a n d cl a s sif y  s y st e mi c h y p er s e n sit i vit y  r e a cti o n s 
 T o m e et r e g ul at or y  e x p e ct ati o n s 
 T o i m pr o v e s u b s e q u e nt cli ni c al m a n a g e m e nt b y  h el pi n g t o di st i n g ui s h b et w e e n t h e v ari o u s 
m e c h a ni st i c b a s e s of a n a p h yl a xi s 
W h e n s h o ul d l a b o r at o r y t e st s b e o bt ai n e d ? 
 I n t h e pr e s e n c e of g e n er ali z e d urti c ari a or if a n a p h yl a xi s i s s u s p e ct e d 
 Aft er t h e p arti ci p a nt h a s b e e n st a bili z e d, o bt ai n a s a m pl e wit hi n 1 -2 h o ur s of t h e e v e nt; 
h o w e v er, s a m pl e s m a y  b e o bt ai n e d a s l at e a s 1 2 h o ur s aft er t h e e v e nt a s a n al y t e s c a n r e m ai n 
al t er e d f or a n e xt e n d e d p eri o d of ti m e. R e c or d t h e ti m e at w hi c h t h e s a m pl e w a s c oll e ct e d. 
 O bt ai n a f o ll o w- u p s a m pl e at t h e n e xt r e g ul arl y s c h e d ul e d vi sit or aft er 4 w e e k s, w hi c h e v er i s 
l at er. 
W h at l a b o r at o r y t e st s s h o ul d b e o bt ai n e d ? 
S e e t h e t a bl e b el o w. 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
89Hypersensitivity Tests Notes
These laboratory tests are bundled in the Clinical Laboratory Operations 
Hypersensitivity Lab Testing Kit.
Selec ted test may  be obtained in the event of anaphylaxis or systemic 
allergic/hypersensitivity reactions.
Lebrikizumab ADAs Assay ed by Lilly -designated laboratory. Results will not be provided to 
the investigative sites.
Lebrikizumab concentrations (PK) Assay ed by Lilly -designated laboratory. Results will not be provided to 
the investigative sites.
Tryptase Assay ed by Lilly -designated laboratory. Results will not be provided to 
the investigative sites.
Note: If a tryptase sample is obtained more than 2 h ours after the event 
(that is, within 2 to 12 hours), or is not obtained because more than 12 
hours have lapsed since the event, obtain urine sample for N -
methy lhistamine testing. Note that for tryptase serum samples obtained 
within 2 to 12 hours of the ev ent, urine N -methy lhistamine testing is 
performed in addition to tryptase testing. Collect the first void urine 
following the event. Obtain a follow -up urine for N -methy lhistamine 
testing at the next regularly scheduled visit or after 4 weeks, whichever is
later.
Drug -specific IgE Will be performed if a validated assay is available.
Assay ed by Lilly -designated laboratory. Results will not be provided to 
the investigative sites.
Basophil activation test Will be performed if a validated assay is available.
Assay ed by Lilly -designated laboratory. Results will not be provided to 
the investigative sites.
Note: The basophil activation test is an in vitro cell based assay that only 
requires a serum sample. It is a surrogate assay for drug specific IgE, but is 
notspecific for IgE.
Complement (C3a and C5a) Assay ed by Lilly -designated laboratory. Results will not be provided to 
the investigative sites.
Cytokine panel (IL ‐6, IL‐1 β, IL‐10) Assay ed by Lilly -designated laboratory. Results will not be provided to 
the investigative sites.
Anti-PLBL2 antibodies Assay ed by Lilly -designated laboratory. Results will not be provided to 
the investigative sites.
Abbreviations: ADA = anti -drug antibody; IgE = immunoglobulin E; IL = interleukin; PK = pharmacokinetic ; 
PLBL -2 = Phospholipase B -Like 2 .
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
9010.6. Appendix 6: Liver Safety: Suggested Actions and Follow -Up 
Assessments
Hepatic evaluation testing
See Secti on 8.2.7 for guidance on appropri ate test select ion.
The Lilly -designated central laboratory  must com plete the analysis of all selected testing except 
for microbi ology testing.
Local  testing m ay be performed in addit ion to central testing when necessary for immediate 
participant m anagement.
Results will be reported if a validated test or calculation is available.
Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -red blood cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
Neutrophils, segmented Gamma -glutamyl transferase (GGT)
Lymphocy tes Creatine kinase (CK)
MonocytesOther Chemistry
Basophils Acetaminophen
Eosinophils Acetaminophen protein adducts
Platelets Alkaline phosphatase isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
CoagulationCopper
Ethyl alcohol (EtOH)
Prothrombin time, INR (PT -INR) Haptoglobin
SerologyImmunoglobulin A(IgA; quantitative)
Hepatitis A virus (HAV) testing: Immunoglobulin G(IgG; quantitative)
HAV total antibody Immunoglobulin M(IgM; quantitative)
HAV IgM antibody Phosphatidylethanol (PEth)
Hepati tis B virus (HBV) testing:Urine Chemistry
Hepatitis B surface antigen (HBsAg) Drug screen
Hepatitis B surface antibody (anti -HBs) Ethyl glucuronide (EtG)
Hepatitis B core total antibody (anti -HBc)Other Serology
Hepatitis B core IgM antibody Anti- nuclear antibody (ANA)
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
91Hematology Clinical Chemistry
Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA) a
HBV DNA d Anti- actin antibody b
Hepatitis C virus (HCV) testing: Epstein -Barr virus (EBV) testing:
HCV antibody EBV antibody
HCV RNA d EBV DNA d
Hepatitis D virus (HDV) testing: Cytomegalovirus (CMV) testing:
HDV antibody CMV antibody
Hepatitis E virus (HEV) testing: CMV DNA d
HEV IgG antibody Herpes simplex virus (HSV) testing:
HEV IgM antibody HSV (Type 1 and 2) antibody 
HEV RNA d HSV (Type 1 and 2) DNA d
Microbiology c Liver kidney microsomal type 1 (LKM -1) antibody
Culture:
Blood
Urine
Abbreviation: INR = internatio nal no rmalized ratio .
aNot required if anti -actin antibody is tested.
bNot required if anti -smooth muscle antibody (ASMA) is tested.
cAssay ed ONLY by investigator -designated local laboratory; no central testing available.
dReflex/confirmation dependent on regulatory requirements, testing availability, or both.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
9210.7. Appendix 7: Examples of Infections That May Be Considered 
Opportunistic
The fo llowing are examples o f infect ions that may be considered opportunistic in the setting of 
biologic therapy  (adapted from  Wint hrop et al . [2015]). This table is provi ded to ai d the 
investigator in recognizing infect ions that may  be considered opportunist ic in the c ontext of 
biologic therapy .This list is not exhaust ive.Infect ions will be categorized by Lilly as 
opportunist ic according to Opportunistic Infections and Biologic Therapies in Immune- Mediated 
Inflammatory Diseases: Consensus Recommendations for Infection Reporting during Clinical 
Trials and Postmarketing Surveillance by Wint hrop etal.(2015).
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
93Examples of Infect ions That May  Be Considered Opportunist ic in the Setting of Bio logic 
Therapy
Bacterial
Barto nellosis (disseminated disease only)
Campy lobac teriosis (invasive disease only)
Legionellosis
Listeriosis (invasive disease only)
Nocardiosis
Tuberculosis
Non-tuberculous mycobacterial disease 
Salmo nellosis (invasive disease only) 
Shigellosis (invasive disease only)
Vibriosis (invasive disease due to Vibrio vulnificus )
Viral
BK virus disease including polyomavirus -associated nephropathy
Cytomegalovirus disease
Hepatitis B virus reactivation
Hepatitis C virus progression
Herpes simplex (invasive disease only)
Herpes zoster (any form)
Post-transplant ly mphoproliferative disorder (Epstein -Barr virus)
Progressive multifocal leukoencephalopathy (PML), John Cunningham (JC) virus 
Fungal
Aspergillosis (invasive disease only)
Blastomycosis
Candidiasis (invasive disease or oropharyngeal, esophageal. Not isolated lingual)
Coccidioidomycosis
Cryptococcosis
Histoplasmosis
Paracoccidioides infections
Penicilliosis
Pneumocystosis
Sporotrichosis
Other invasive molds: Mucormycosis ( zygomycosis) ( Rhizopus , Mucor, and Lichtheimia ), 
Scedosporium /Pseudallescheria boydii , Fusarium
Parasitic
Leishmaniasis (visceral only)
Strongyloidiasis (hyperinfection syndrome or disseminated disease)
Microsporidiosis
Toxoplasmosis
Trypanosoma cruzi infection (Chagas disease progression) (disseminated disease only)
Cryptosporidiosis (chronic disease only)
Source: Adapted from Winthrop et al. (2015).
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
9410.8. Appendix 8: American Academy of Dermatology Consensus Criteria 
for Chronic Atopic Dermatitis
Atopic derm atitis: Diagnosis recommendat ions
Patients wi th presumed ADshoul d have thei r diagnosis based on the criteria summarized below. 
On occasion, skin biopsy  specimens or other tests (such as serum immunoglobulin E, potassium 
hydrox ide preparation, patch testing, and/or genetic testing) may be helpful to rule out other or 
associ ated skin condit ions.
Level o f Evidence: III Strength of Reco mmendat ion: C
Essential features —must be present:
Pruri tus 
Eczem a (acute, subacute, chronic)
Typical  morphol ogy and age-specific patterns *
Chronic or relapsing history
*Patterns include:
Facial, neck, and extensor involvement in infants and children
Current or previous flexural lesio ns in any  age group
Sparing of the groin and axillary regions
Important features —seen in most cases, adding support to the diagnosis:
Early age of onset
Atopy
Personal and/or family history
Immunoglobulin E reactivit y
Xerosis
Associ ated features —These clinical associat ions help to suggest the diagnosis of atopic 
dermatitis but are too nonspecific to be used for defining or detecting atopic dermat itis for 
research and epidemio logic studies:
Atypical vascular responses (e .
g.,facial pallor, white dermographism, delayed blanch 
response)
Keratosis pilaris/pit yriasis alba /hyperlinear palms/icthy osis
Ocul ar/peri orbital changes
Perifo llicular accentuation/lichenification/prurigo lesio ns
Exclusio nary condi tions 
—It should be noted that a diagnosis of atopic dermat itis depends on 
excluding condit ions, such as:
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
95Scabies
Seborrh eic derm atitis
Contact dermat itis (irritant or allergic)
Icthy oses
Cutaneous T -cell lympho ma
Psori asis 
Photosensit ivity dermatoses
Immune deficiency diseases
Erythroderma of other causes
Adapted from  Eichenfield et al. 2014.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
9610.9. Appendix 9: Provisions for Changes in Study Conduct During 
Exceptional Circumstances
Except ional circumstances, such as pandemics or natural disasters, may  cause disrupti ons to the 
conduct of the study . These disruptions may limit the abilit y of the invest igators, participants, or 
both to attend on -site visi ts or to conduct planned study  procedures.
In an except ional circumstance, after receiving the sponsor’s written approval, sites may  
implement changes if permitted by local regulat ions. Such changes are intended to mit igate risks 
of participants missing visits, allo w parti cipants to continue safely in the study , and maintain the 
data integrit y of the study .GCP com pliance and minimizat ion of ri sk to study  integrity are 
important considerations. Ensuring the safet y of study  parti cipants is the prevailing 
consideration.
Once restri ctions are lifted, the sponsor will notify sites that these provisio ns for changes in study  
conduct will be reversed and routine study  conduct restored.
The fo llowing changes in study  conduct captured in this Appendix will not be considered 
protocol  deviat ions. Mi ssing data will be captured as protocol deviat ion(s). Changes in study  
conduct not described in this Appendix, or not consistent with applicable local regulat ions, are 
not allowed.
Informing ethical r eview boards (ERBs)
Ethical  review boards and regulatory bodies will be notified as early as possible to communicate 
implementation of changes in study  conduct due to except ional circumstances. To protect the 
safet y of study  participants, urgent changes may be implemented before such co mmu nicati ons 
are made, but all changes will be reported as soon as possible fo llowing implementation.
Remote visits
Under except ional circumstances, som e of the study  visits may  be conducted remotely (in 
addition to the rem ote visi ts already  allowed by  the study  design). Rem ote vi sits may  be 
conducted virtually and/or as m obile heal th care visi ts, if permi tted by  local laws and regulations 
(see below for details).
Virtual visit (telephone/telemedicine)
Telephone or techno logy-assisted virtual visits (telemedicine) to complete appropriate 
assessments are acceptable. The study  site shoul d capture the visit location and method with a 
specific explanat ion for any  data missing because of missed in -person site visits in source 
document s. Assessments to be completed during a virtual visit include , but are not limited to:
AEand SAEreports
concomitant medicat ions, and
compliance wi th the patient di ary
Mobile health care visit
Addit ional consent fro m the parti cipant will  be obtained for those who participate in home healt h 
care services.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
97If permitted by  local regulat ions, m obile visi ts may  be perf ormed at locati ons other than the 
study  site (e.g., participant’s ho me) when part icipants cannot travel to the site due to exceptional 
circumstances. These will be performed by  a qualified hom e healt h care service provider or 
trained site personnel, fo llowing sponsor written approval. Procedures performed may include, 
but are not limited to :
taking blood samples
collect ing urine samples for pregnancy testing
conducting physical assessments , depending on the qualifications of the mobile ho me 
healt h care provi der
administering patient -reported outcomes
administering study  intervention, and
collect ing healt h information. 
Before administering study  drug at home, participants and/or caregivers will be adequately 
trained on at- home study drug administration (unless they have already  been trained; see also the 
section “Study  drug and ancillary supplies” below).
Please note that requirements related to the reporting of SAEs rem ain unchanged. Ev ery effort 
shoul d be made for the participant to return to on -site visi ts as soon as reasonably possible, while 
ensuring the safet y of the pa rticipant and invest igatio nal site staff. 
Study drug and ancillary supplies
Under except ional circumstances, the sponsor or designe ewill determine appropriate actions to 
supply/resupp ly participants with the study  drug and ancillary  supplies.
The fo llowing requirements must be met:
sponsor approves the alternative method of delivery, taking local regulatory  requi rements 
into considerat ion
participant consents verbally  to al ternate m ethod of delivery
participants or thei r caretakers are appropriately trai ned on at-home administration of the 
study  drug (unless they  have al ready  received that training) ; the ho me healt h care 
provi der will observe the participant or caregiver administer the study  drug f or the first 
time.
oif the study  drug is administered at home, participants will need to record the 
details about the inject ions in the patient diary  (regardl ess of whether the at -home 
study  drug administrati onisdone by the participant him -/herself, caregiver, or 
mobile ho me healt h care provider). For the at -home administration informat ion, 
the sam e electroni c patient di ary will be used as for recording the PROs.
site/sponsor confirms the participant’s receipt of the trial supplies
site/sponsor confirm appropriate ethics review board notificat ion
alternate deli very of the study  drug shoul d be perform ed in a m anner that does not 
compromise treatment blinding and ensures study  drug integrity. The exist ing protocol 
requi rements for product accountabilit y remain unchanged. 
when delivering supplies to a location oth er than the study  site (e.g., parti cipant’s home)
oparticipant consent must include provisio n of any  personal  informat ion
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
98oinvestigator/sponsor should ensure oversight of the shipping process to ensure 
accountabilit y and product qualit y (i.e., storage condit ions and intact packaging 
upon recei pt)
additional instructi ons shoul d be provi ded to the parti cipant on how to return any  unused 
or com pleted tri al supplies.
Local laboratory option
In exceptional circumstances, to ensure participant safet y and wi th the sponsor ’s prior wri tten 
approval , local laboratory  testing m ay be conducted in lieu of central laboratory  testing.
However, central laboratory  testing m ust be retained for the following: 
Vaccine -specific antibody  titer levels :
oAnti-tetanus toxoi d IgG antibody , and
oMeningococcal Group C serum bactericidal ant ibodies (hSBA)
PKsamples
Immunogenicit y (ADA) samples
Pharmacogenet ics sample
The l ocal laboratory  must be qualified in accordance with local regulat ions.Clinically significant 
laboratory  finding s will be reported as an AEin the AE eCRF. 
Screening period guidance 
If the study  screening window exceeds 30 days due to the except ional circumstances , the 
participant woul d be considered a screen failure and may  be rescreened.
The screening procedure s per the SoA in the protocol should be fo llowed (starting at Visit 1) to 
ensure parti cipant eligibilit y by rando mization visit (Visit 2). Before rescreening, the participant 
must si gn a new ICF and receive a new ident ificat ion number through IWRS.
Increasing visit window(s) for the key endpoint visits
Parti cipants shoul d com plete the vaccine administration visit ( Visit 8/Week 12)and the final 
study  endpoint visi t (Visit 10/Week 16 ) as per original SoAwhenever possible and deemed safe 
to do so by the invest igator .However, in order to maximize the abilit y for such on -site visi ts, 
minimize missing data, and preserve the intended conduct of the study , the visi t windows may be 
adjusted as fo llows, upon specific guidance fro m the sponsor:
For Visit 8 (Week 12 ), to +7/ -3 days
For all dosing visit s and Visit 10 (Week 16), to +7 days
Whenever possible, the visit intervals should be adjusted to allow 4 weeks between Visit 8 
(Week 12)and Visit 10 ( Week 16 ),to allow for the highest level o f vaccine resp onse to be seen.
Documentation
Changes to study conduct
Changes to study  conduct will be docum ented as the fo llowing:
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
99Sites will need to ident ify and document the details of how participants, visit types, and 
activit ies conducted were affected by except ional circumstances. Dispensing/shipment 
records of study  intervent ion and rel evant communicat ions, including delegat ion, should 
be filed wit h site study records.
The site should document the participant’s verbal consent for having remote visits and 
remote dispensing of study  drug , ancillaries and diaries, prior to implementation of these 
activit ies. 
Source document(s) that are generated at a locati on other than the study  siteshoul d be 
part of the invest igator’s source docum entati on and shoul d be transferred to the site in a 
secure and t imely manner. 
Missing data and other protocol deviations 
The study  site shoul d capture specific explanat ion for any missing data and other protocol 
deviat ions in source do cuments .This information will also be captured by  the m onitors in the 
monitoring system . While protocol  deviat ions m ay be unavo idable in an exceptional 
circumstance, docum entati on of  protocol  deviat ions and missing data will be important for data 
analysis and reporti ng.
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
10010.10. Appendix 10: Abbreviations
Term Definition
AD atopic dermatitis
ADA anti-drug antibod y
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
anti- HBc hepatitis B core antibody
anti- HBs hepatitis B surface antibody
AST aspartate aminotransferase
ATC anatomical therapeutic chemical
BCG Bacillus Calmette -Guerin
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the participant is not, or vice versa , or when the sponsor is aware of the 
treatment but the investigator and/his staff and the participant are not.
A double -blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the 
participants are aware of the treatment received.
BSA Body Surface Area
CI confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
CK creatinine kinase
CMV cytomegalovirus
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality , purity , durability , reliability , safety  or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CONSORT Consolidated Standards of Reporting Trials
CRF case report form
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
101Term Definition
CTA Clinical Trial Agreement
DMC data monitoring committee
DSM B Data Safety Monitoring Board
EASI Eczema Area and Severity Index
EASI -75 ≥75% reduction from baseline in EASI score
EASI -90 ≥90% reduction from baseline in EASI score
EBV Epstein -Barr virus
ECG electrocardiogram
eCOA electronic Clinical Outcome Assessment
eCRF electronic case report form
EDC electronic data capture system
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERB ethical review board
ERCP endoscopic retrograde cholangiopancreatography
ET early  termination
FLG filaggrin
FSH follicle stimulating hormone
GCP good clinical practice
cGMP current Good Manufacturing Practice
GGT gamma -glutamyl transferase
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HDV hepatitis D virus
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
102Term Definition
HIPAA Health Insurance Portability and Accountability Act
HIV human immunodeficiency virus
hSBA human complement serum bactericidal assay
huIgG4 humanized monoclonal immunoglobulin G4 antibody
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IFN-γ interferon gamma
IgA immunoglobulin A
IGA Investigator Global Assessment
IgE immunoglobulin E
IgG immunoglobulin G
IL interleukin
Informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate. Informed consent is 
documented by means of a written, signed and dated informed consent form.
INR internatio nal no rmalized ratio
investigational 
productA pharmaceutical form of an act ive ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauth orized indication, or marketed products used to 
gain further information about the authorized form.
IRB Institutio nal Review Boards
ITT intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a participant (that is, the 
planned treatment regimen) rather than the actual treatment given. It has the 
consequence that participant allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IUD intrauterine device
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
103Term Definition
IUS intrauterine hormone -releasing system
IWRS interactive web -response sy stem
LLOQ lower limit of quantitation
LOR loricrin
LTBI latent tuberculosis infection
MCMC Markov Chain Monte Carlo
MCV Meningococcal (Groups A, C, Y, and W -135) Oligosaccharide Diphtheria CRM197 
Conjugate Vaccine (GlaxoSmithKline)
MRCP magnetic resonance cholangiopancreatography
non-WOCBP women of nonchildbearing potential
NRS Numeric Rating Scale
Participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
PFS-NSD prefilled syringe with needle safety device
PK pharmacokinetics
POEM Patient-Oriented Eczema Measure
PP per protocol
PRO patient -reported outcomes
PROMIS Patient-Reported Outcomes Measurement Information System
PT-INR prothrombin time international normalized ratio
PUVA phototherapy and photochemotherapy
Q2W once ever y 2 weeks
SAE serious adverse event
SAP Statistical Analysis Plan
Screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SD standard deviation
SERM selective estrogen receptor modulator
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
104Term Definition
SoA Schedule of Activities
TBL total bilirubin level
TCI topical calcineurin inhibitors
TCS topical corticosteroids
Tdap Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (Sanofi)
TE-ADA treatment -emergent antidrug antibody
TEAE Treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal r elationship 
with this treatment.
TSLP thymic stromal ly mphopoietin
ULN upper limit of normal
WHO World Health Organization
WOCBP wome n of childbearing potential
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
10511. References
Auriemma M, Vianale G, Amerio P, Reale M. Cy tokines and T cells in atopic dermat itis. 
EurCytokine Netw . 2013;24(1):37 -44.https://doi.org/ 10.1684/ecn.2013.0333
Bieber T. Atopi c dermat itis. N Engl J Med. 2008;358(14):1483 -1494.
https://doi .org/10.1056/NEJMra074081
Bieber T. Atopic dermat itis 2.0: from the clinical phenoty pe to the m olecular taxonomy and 
stratified medicine. Allergy. 2012;67(12):1475 -1482. https:// doi.org/ 10.1111/all.12049
Bieber T, Novak N. Pathogenesis of atopic dermat itis: new developments. Curr Allergy Asthma 
Rep.2009;9(4):291 -294. https:// doi.org/10.1007/s11882 -009-0041-2
Blauvel t A, Simpson EL, Ty ring SK, et al . Dupilumab does not affect correlates of vaccine -
induced immunit y: arando mized, placebo -controlled trial in adults wit h moderate -to-severe 
atopic dermatit is. J Am Acad Dermatol . 2019;80(1):158 -167. 
https:// doi.org/ 10.1016/j.jaad.2018.07.048
[CDC] . Centers for Disease Control and Prevent ion.Interpretation of hepat itis B sero logic test 
resul ts. Accessed July 29, 2020. https://www.cdc.gov/hepat itis/hbv/pdfs/Sero logicChartv8.pdf 
Charm an CR, Venn AJ, Williams, HC. The p
atient-oriented eczema measure: devel opment and 
initial validat ion of a new tool for measuring atopic eczema severit y from the pati ents’ 
perspective. Arch Dermatol . 2004;140
(12):1513 -1519.
https:// doi.org/ 10.1001/archderm.140.12.1513
Choy DF, Hsu DK, Seshasayee D, et al. Comparat ive transcriptomic analyses of atopic 
derm atitis and psoriasis reveal shared neutrophilic inflammat ion. J Allergy Clin Immunol. 
2012;130(6):1335 -1343. https://doi. org/10.1016/j.jaci.2012.06.044
Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic 
derm atitis: sect ion 1. Diagnosis and assessment of atopic dermatit is. J Am Acad Dermatol . 
2014;70(2 ):338 -351. doi:10.1016/j.jaad.2013.10.010
Esche C, de Benedetto A, Beck LA. Kerat inocytes in atopic dermat itis: inflammatory  signals. 
Curr Allergy Asthma Rep. 2004;4(4):276 -284. https:// doi.org/ 10.1007/s11882-004-0071-8
Flohr C, Irvine AD. Sy stemic therapies for severe atopic dermatit is in children and adults. 
JAllergy Clin Immunol . 2013;132(3):774 -774. https:// doi.org/ 10.1016/j.jaci.2013.03.016
Hamid Q, Naseer T, Minshall EM, et al. In vivo expressio n of IL -12 and IL -13 in atopi c 
derm atitis. J Allergy Clin Immunol. 1996;98(1):225 -231. https://doi.org/ 10.1016/s0091-
6749(96)70246-4
Hanifin JM, Thurston M, Omoto M, et al. The eczem a area and severit y index (EASI): 
assessment of reliabilit y in atopic dermatit is. EASI Evaluator Group. Exp Dermatol . 
2001;10(1):11 -18.https://doi.org/ 10.1034/j.1600- 0625.2001.100102.x
He JQ, Chan -Yeung M, Becker AB, et al. Genet ic variants of the IL13 and IL4 genes and atopic 
diseases in at- risk children. Genes Immun. 2003;4(5):385-389.
https://doi .org/ 10.1038/sj .gene.6363985
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
106Howell MD, Fairchild HR, Kim BE, et al. Th2 cy tokines act on S100/A11 to downregulate 
keratinocy te different iation. J Invest Dermatol. 2008;128(9):2248 -2258.
https://doi .org/ 10.1038/jid.2008.74
Hummelsho j T, Bodtger U, Datta P, et al. Associ ation between an interl eukin -13 prom oter 
polymorphism and atopy . Eur J Immunogenet. 2003;30(5):355 -359.
https://doi .org/ 10.1046/j.1365 -2370.2003.00416.x
Jeong CW, Ahn KS, Rho NK, et al. Different ial in vivo cy tokine m RNA expressio n in lesional 
skin of intrinsic vs. extrinsic atopic dermat itis patients using semiquant itative RT -PCR. Clin Exp 
Allergy. 2003;33(12):1717 -1724. https://doi.org/ 10.1111/j.1365 -2222.2003.01782.x
Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermat itis is associat ed with a decrement in 
healt h-related qualit y of life. Int J Dermatol . 2002;41(3):151 -158. https://doi.org/ 10.1046/j.1365 -
4362.2002.01436.x
Kim BE, Leung DY M, Boguniewicz M, Howell MD. Loricrin and involucrin expressio n is 
down -regulated by  Th2 cy tokines t hrough STAT -6. Clin Immunol . 2008;126(3):332 -337.
https://doi .org/ 10.1016/j.clim.2007.11.006
Kim Y, Won S. Adjusted proportion difference and confidence interval in stratified rando mized 
trials. PharmaSUG, Chicago, May  2013. Accessed July 29, 2020. 
https://www.pharmasug.org/proceedings/2013/SP/PharmaSUG -2013- SP04.pdf
La Grutta S, Richiusa P, Pizzolanti G, et al. CD4(+)IL -13(+) cells in peripheral blood well 
correl ates wi th the severi ty of atopi c derm atitis in children. Allergy. 2005;60(3):391 -395.
https://doi .org/ 10.1111/j.1398 -9995.2005.00733.x
Mitterm ann I , Aichberger KJ, B ünder R, et al. Autoimmuni ty and atopi c derm atitis. Curr Opin 
Allergy Clin Immunol . 2004;4(5):367 -371. https://doi.org/ 10.1097/00130832-200410000-
00007
Neis MM, Peters B, Dreuw A, et al. Enhanced expressio n levels o f IL-31 correlate with IL -4 and 
IL-13 in atopic and allergic contact dermat itis. J Allergy Clin Immunol. 2006;118(4):930 -937.
https://doi .org/ 10.1016/j.jaci.2006.07.015
Newton L, DeLozier AM, Griffit hs PC, et al. Exploring content and psy chometric validit y of 
newly developed assessment tools for itch and skin pain in atopic dermat itis. J Patient Rep 
Outcomes . 2019(16);3(1):42. https://doi.org/ 10.1186/s41687-019-0128-z
Novak N, Kruse S, Kra ft S, et al . Dichotomic nature of atopic dermat itis reflected by co mbined 
analysis of mo nocy te immunophenoty ping and singl e nucleoti de polymorphisms o f the 
interleukin -4/interleukin -13 receptor gene: the dichotomy  of extrinsic and intrinsic atopic 
derm atitis. J Invest Dermatol. 2002;119(4):870 -875. https://doi.org/ 10.1046/j.1523 -
1747.2002.00191.x
[PROMIS] .Anxiet y. Published March 01, 2019. Accessed July 29, 2020.
https://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Anxiet y_Scoring_Manual.
pdf 
[PROMI S].Depression. Published February 28, 2019. Accessed July 29, 2020.
https://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Depressio n_Scoring_Manu
al.pdf 
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
107[PROMIS] . PROMIS website. Accessed July 29, 2020. https://www.healthmeasures.net/explore -
measurement -system s/promis 
Purwar R, Werfel T, Witt mann M. IL -13-stimulated human keratinocy tes preferentially attract 
CD4+CCR4+ T cells: possible role in atopic dermatit is. J Invest Dermatol . 2006;126(5):1043-
1051. https://doi.org/ 10.1038/sj.jid.5700085
Sampson HA, Mu ñoz-Furlong A, Campbell RL, et al. Second symposium on the definit ion and 
management of anaphylaxis: summary report -Second National Inst itute of Allergy and 
Infectious Disease/Food Allergy  and Anaphyla xis Network symposium. J Allergy Clin Immunol
. 
2006;117(2):391 -397. https://doi.org/ 10.1016/j.jaci.2005.12.1303
Simon D, Wollenberg A, Renz H, Simo n HU. Atopic derm atitis: Co llegium Internat ionale 
Allergo logicum (CIA) update 2019. Int Arch Allergy Immunol. 2019;178(3):207 -218.
https://doi .org/ 10.1159/000497383
Suárez-Fariñas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatit is shows similar TH2 and 
higher TH17 immune act ivation compared with extrinsic atopic dermat itis. J Allergy Clin 
Immunol . 2013;1
32(2):361 -370. https://doi.org/10.1016/j.jaci.2013.04.046
Tanei R. Atopic dermat itis in the elderly. Inflamm Allergy Drug Targets. 2009;8(5):398 -404.
https://doi .org/ 10.2174/1871528110908050398
Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL -13 in lesio nal 
skin of atopic dermatit is. Arch Dermatol Res. 2004;295(11):459 -464.
https://doi .org/10.1007/s00403-004-0455-6
Tipton M,Daly W, Senders S, et al .MenACWY -CRM conj ugate vaccine booster dose given 4-6 
years after priming: results fro m a phase IIIb, mult icenter, open label study  in ado lescents and 
adults. Vaccine . 2019;37(42):6171- 6179. https://doi.org/ 10.1016/j.vaccine.2019.08.065
Van Bever HP S, Llanora G. F eatures of childhood atopic dermatit is. Asian Pac J Allergy 
Immunol . 2011;29(1):15 -24.
Weidinger S, Beck LA, Bieber T, et al. Atopi c dermat itis. Nat Rev Dis Primers. 2018;4(1):1.
https://doi .org/ 10.1038/s41572-018-0001-z
Weidinger S, Novak N. Atopic dermat itis. Lancet. 2016;387(10023):1109-1122.
https://doi .org/ 10.1016/S0140 -6736(15)00149-X
Werfel T, Allam JP, Biedermann T, et al. Cellular and mo lecular immuno logic mechanisms in 
patients wi th atopic derm atitis. J Allergy Clin Immunol. 2016;138(2):336 -349.
https://doi .org/ 10.1016/j.jaci.2016.06.010
Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? 
J Allergy Clin Immunol. 2008;121(4):947 -954. https://doi.org/ 10.1016/j.jaci.2007.11.004
Wint hrop KL, Novosad SA, Baddley JW, et al. Opportunist ic infect ions and bio logic therapies in 
immune -mediated inflammatory  diseases: consensus recommendat ions for infecti on reporting 
during clinical trials and postmarket ing surveillance. Ann Rheum Dis .2015;74 (12):2107 –2116.
https://doi.org/ 10.1136/annrheumdis -2015-207841
CONFIDENTIAL Protocol  J2T-MC-KGAK /DRM06- AD18
108Yan X, Su XG. Stratified Wilson and Newco mbe confidence intervals for mult iple bino mial 
proporti ons. Statistics in Biopharmaceutical Research . 2010;2(3):329 -335. 
doi:10.1198/sbr.2009.0049
Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspect ives on the management of atopic 
derm atitis. J Allergy Clin Immunol . 2006;118(1):226 -232.
https://doi.org/ 10.1016/j.jaci.2006.02.031
L e o  D o c u m e n t  I D  =  3 0 5 7 7 e 5 c - a 4 f b - 4 4 d 4 - 9 b 5 a - 8 a 9 2 6 d 6 5 4 7 f c 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  0 5 - A u g - 2 0 2 0  2 0 : 5 0 : 2 1  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  0 5 - A u g - 2 0 2 0  2 1 : 2 6 : 2 2  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 